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ABSTRACT

STRUCTURE-FUNCTION STUDIES OF THE cAMP-DEPENDENT
PROTEIN KINASE IN VITRO AND IN INTACT CELLS

Gary Z. Morris
Old Dominion University, 2006
Director: Dr. Stephen J. Beebe

There are 518 protein kinase genes in the human genome; this constitutes about
1.7% o f all human genes. The cAMP-dependent protein kinase (PKA) serves as the
prototypic model for the study o f kinases because it contains a conserved catalytic core
shared with all eukaryotic kinases, it is the simplest kinase, and it is one o f the bestcharacterized serine/threonine kinases. PKA is ubiquitous in mammals and regulates
multiple physiological mechanisms such as the cell cycle, apoptosis, cell motility, energy
metabolism, and gene transcription through a well-defined intracellular signaling
pathway. While PKA clearly has a central physiological role it is still unclear how PKA
mediates multiple physiological mechanisms at the cellular level. Four approaches were
used to explore this question using two PKA catalytic subunits, C a and Cy, which share
83% identity in primary structure but differ in function. The first approach sought to
identify differences in primary structure between Cy and C a, which may define
functional differences between them. To this end chimeras were generated, swapping the
carboxyl and amino termini between C a and Cy and were evaluated for functionality
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through CREB-mediated reporter assays. Wild type C a and Cy induced CREB-mediated
transcriptional activation, but the chimeras failed to exhibit any activity. The second
approach sought to characterize phosphorylation differences between purified PKA-Cy
and PKA -Ca that defines their physiological function. Two novel phosphorylation sites
were identified on both isoforms by tandem mass spectrometry analysis (Cy S14 and
Ca/Cy S259). It was also determined that Cy expressed in Sf9 insect cells, like C a
expressed in mammalian cells, is phosphorylated at T 197 and S3 3 8 and the modification
at T197 is important to the function o f both isoforms. The third approach sought to
characterize the kinetic mechanism o f PKA-Cy through determination o f the rate for the
reaction-limiting step, which was found to be 9-times slower than that o f C a. The final
approach sought to identify Cy expression in the cell through the use o f a new Cy-specific
antibody. Cy expression was identified following differentiation o f U-937 cells
suggesting a novel function for Cy in the cell.
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CHAPTER I
SIGNIFICANCE, SPECIFIC AIMS AND BACKGROUND

SIGNIFICANCE
There are 518 protein kinase genes in the human genome (2); this constitutes about
1.7% of all human genes (2). Kinases allow physiologic extracellular stimuli to elicit
specific cellular response through signal transduction. The cAMP-dependent protein
kinase (PKA) serves as the prototypic model for the study o f kinases because it contains a
conserved catalytic core shared with all eukaryotic kinases; it is the simplest kinase; and
it is one o f the best-characterized serine/threonine kinases (3). PKA is ubiquitous in
mammals (4-6) and regulates multiple physiological mechanisms such as the cell cycle
(7), apoptosis ( 8 ), cell motility (9), energy metabolism (10), and gene transcription (11)
through a well-defined intracellular signaling pathway (12,13). Deregulation o f PKA is
found in several diseases including Carney complex (14,15),

Systemic Lupus

Erythematosus (16,17), breast cancer (18), and prostate cancer (19). PKA knockout mice
demonstrate deficiencies in neuronal pathways including decreased sensitivity to
nocioceptive responses and alterations to synaptic plasticity (4). While PKA clearly has a
central physiological role it is still unclear how PKA mediates multiple physiological
mechanisms at the cellular level.

T he m od el for this dissertation is the Journal o f B io lo g ica l C hem istry.
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SPECIFIC AIMS
cAMP-dependent protein kinase (PKA) mediates multiple physiological functions
including hormone secretion, energy metabolism, apoptosis, and cellular differentiation in
response to physiological stimuli. Thus, it is clear that PKA function is crucial to normal
cell physiology and homeostasis. Therefore understanding the roles o f PKA in the cell is a
focus of ongoing scientific research. To this end, there is a large body o f scientific literature
focusing on two o f the PKA catalytic (C) subunits, C a and Cp. However less research has
been done on the third PICA C-subunit, Cy. Recently we established that C a and Cy, while
sharing sequence homology (83% identity in protein primary sequence), do not mediate
transcription through the same promoter sequence or transcription factors and differ in their
phosphorylation efficiency for multiple substrates tested (20). Research outlined in this
dissertation was performed to determine structure-function differences between C a and Cy
that explain how they mediate transcription through different mechanisms and why they
differ in their catalytic measurements.
Specific Aim 1: To identify differences in primary structure between PKA-Cy and
PKA-Ca that defines their physiological function in intact cells. Our hypothesis is that
differences in C a and Cy primary structures are responsible in part for differential
transcriptional regulation. Co-transfections o f wild-type and mutated C-subunits with a
PKA-selective reporter-vector will be used to characterize and correlate the C-subunit
structure with their function.
Specific Aim 2: To characterize post-translational differences between purified
PKA-Cy and PK A-Ca that defines their physiological function. Our hypothesis is that
differences in Km and Vmax for physiological substrates are attributed in part to post-
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translational differences between C a and Cy. Liquid chromatography-tandem mass
spectrometry analysis o f purified recombinant histidine-labeled C a and Cy will be used to
characterize post-translational phosphorylation differences between the C-subunits.
Specific Aim 3: To characterize the kinetic mechanism for PKA-Cy through
determination of the rate constants for each catalytic step of the phosphotransferase
reaction. Our hypothesis is that Cy functions through the same kinetic mechanism as C a
but has slower rate constants. Stopped-flow analysis o f purified recombinant proteins will
be used to characterize pre-steady state kinetics necessary for establishing rate constants
for each catalytic step.
The results presented in this dissertation suggest that one mechanism by which
PKA mediates multiple physiological mechanisms within the cell is through expression of
multiple isoforms. Here we focused on the two most divergent catalytic subunits, C a and
Cy to study this mechanism. The following is a brief background introducing the kinase
enzyme along with some background on PKA that 1) coincide with the specific aims
outlined in this section, 2) coincide with work proposed for my Porter Physiology
Fellowship and 3) coincide with different manuscripts that have either been published,
submitted or in preparation for submission. Each o f the following chapters will contain a
more specific background pertaining to the focus o f that chapter.
BACKGROUND
Protein kinases are an evolutionarily conserved protein fa m ily - A kinase is an
enzyme that catalyzes the hydrolysis o f the y-phosphate (the terminal phosphoryl group) on
a nucleotide triphosphate (NTP) and the covalent binding of this phosphate to a target
substrate. The Enzyme Commission o f the International Union o f Biochemistry and
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Molecular Biology name for a kinase is a phosphotransferase. The term kinase is a lay-term
derived from the Greek word kinein, which means to move towards1. In the context o f the
kinase the name refers to the movement of the phosphoryl group from NTP to the target
substrate by the kinase. Figure 1 shows a timeline identifying important events related to
the study o f the kinase enzyme in the past century, including the “purification” of
phosphorylase kinase in 1943, the first characterization of a kinase, casine kinase (now
casine kinase 2), in 1954 and the description o f the human kinome in 2002. The human
genome contains at least 663 kinase genes (21). O f these, 518 are protein kinases, about
half the number initially predicted (2, 22). Thus, almost 2% o f the human genome is
dedicated to the expression of this protein family suggesting that the function o f this protein
is very important to mammals (2). Protein kinases have been divided into eight distinct
groups based on their structure and function (AGC: containing PKA, PKG, PKC families;
CK1: casein kinase 1 group; STE: homologous to yeast sterile 7, sterile 11, sterile 20
kinases group; TKL: tyrosine kinase-like group; TK: tyrosine kinase group; CMGC:
containing CDK, MAPK, GSK3, CLK families, and CAMK: calcium/calmodulindependent kinase group) (2 ). Figure

1

also shows how the study o f kinases has increased in

an exponential manner over the last forty years, based on the number o f yearly publications
found in Entrez PubMed (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi). Research seems
to be nearing a plateau, which may indicate that the rate at which scientist are able to study
kinases, generate results and publish them using current technology is reaching a limit. The
time line presented in Figure 1 also suggests that key basic science discoveries in the kinase
field seem to be made about every nine years.

1 B ased on a personal em ail com m unication from T on y Hunter. P lease see A p p en d ix A .
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Kinases utilize an evolutionarily conserved mechanism and are found in organisms o f all
three Domains o f life: Archaea, Bacteria and Eucarya (23-25). Kinases are placed in broad
groups that include protein kinases, which phosphorylate proteins, and lipid kinases, which
phosphorylate lipids generating secondary messengers in the cell. Some kinases, referred to
as ‘small molecule kinases,’ do not fit in any o f these groups such as hexokinase
(phosphorylates glucose), choline kinase (phosphorylates choline) or ethanolamine kinase
(phosphorylates ethanolamine) (26). Kinases are also classified based on the nature o f their
substrate. These classifications include serine/threonine kinases, tyrosine kinases, histidine
kinases, and antibiotic kinases, which are bacterial kinases, associated with bacterial
antibiotic resistance and found to be closely associated to eukaryotic serine/threonine
kinases (27). The prevalent kinases found in the Eukaryotes are the serine/threonine and
tyrosine protein kinases (2). In recent years serine/threonine protein kinases have also been
identified in bacteria and archaeabacteria (25,28). Histidine protein kinases are found in
bacteria, archaeabacteri, plants, fungi, and slime mold as part o f a two-component system,
where the kinase autophosphorylates on a histidine residue (the first component), transfers
this phosphoryl to an aspartate on the effector domain (the second component) leading to
the response to extracellular stimuli (25,28,29).
While the structure and chemical nature o f the substrates differ between the kinase
groups, most protein kinases share sequence and structural homology through their
catalytic core, which consists of approximately 250-300 amino acids (23). O f the 518
protein kinases in the human genome, 478 share homology in this region (2).
Mitochondrial pyruvate dehydrogenase kinases have been found to share sequence and
structural homology with prokaryotic histidine kinases (30). Histidine kinases and
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eukaryotic kinases share some sequence homology through the nucleotide binding domain
and structural homology through the small lobe (29), suggesting that all kinases evolved
from a ‘protokinase’ present prior to the divergence o f the three domains o f life(29). This
hypothesis depends on the methods and criteria used to classify sequence homology and
not all literature agrees that there is homology between the atypical prokaryotic kinases and
eukaryotic kinases (23). Furthermore, not all eukaryotic kinases share sequence homology
as demonstrated by a group o f 40 kinases in the human kinome classified as atypical
kinases because they lack sequence homology with the rest of the kinases (2). However all
o f these kinases have been reported to have phospho-transferase activity and many share
structural homology with typical eukaryotic kinases. The homology o f kinases among
organisms and Domains will be easier to discern once kinomes are identified for all
organisms used in these comparison studies. Such work is presently underway in
archeabacteria (25). The presence of homologous kinases among Domains is more likely to
be due to horizontal transfer between organisms than to independent evolutionary pathways
(30). The transfer of a phosphate group as a signal in the organism has been conserved
through the diverse groups o f kinases found in all three life Domains, making the theory of
a protokinase very attractive. The evolutionarily conserved nature o f the protein kinase
family allows for structure-function relationship characterization o f this group through use
o f structurally simple members o f this family.
The best-characterized protein kinase is the cAMP-dependent protein kinase (PKA,
EC 2.7.1.37) (31). About 5% o f the nearly 340,000 papers published on kinases found on
Entrez PubMed are on PKA and, as Figure 1 demonstrates, PKA was the first for many
developments in the kinase field. PKA was the first kinase for which a linear structure was
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determined through a molecular biology approach, allowing for the generation of
recombinant PKA and its subsequent characterization through recombinant protein
technology (32). PKA was also the first kinase to be crystallized, allowing for its structure to
be elucidated (33). PKA has a relatively simple structure, consisting o f 350 amino acids
including the 280 residues that constitute the conserved kinase catalytic core along with 70
more amino acids, which also participate in the catalytic function o f the enzyme. The PKA
catalytic subunit consists of a bilobal structure shared by all protein kinases (33). The
combined knowledge of PKA kinetics and structure have contributed to the present
understanding of the kinase catalytic mechanism (34-38). Because o f this wealth of
information the PKA catalytic subunit serves as a template for the structural classification of
all kinase domains (23,39,40) and an excellent model to study kinase structure-function
relationships.
PKA is very important to organism physiology- PKA is present at varying
concentrations in all tissue types (41-43) and exists in the cell as an inactive tetrameric
holoenzyme composed of a regulatory (R) subunit dimer and two monomeric C subunits
(31,44). The holoenzyme (R2C2) can be classified into types I and II PKA determined by
the R subunit isoform present in the holoenzyme. There are four known Homo sapiens
genes for the R subunit: R Ia, Rip, R lla, and RIIp. Classically, PKA type I elutes from a
DEAE column at concentrations below 0.1 M NaCl and type II elutes at concentrations
greater than 0.1 M NaCl (44). There are four genes for the C-subunit expressed in Homo
sapiens: Ca, Cp, Cy and PrKX (45,46). The PKA catalytic subunits are members o f the
AGC serine/threonine kinase group (2), and phosphorylate hundreds o f substrates involved
in numerous physiological processes (1). Each of the C-subunit isoforms is expressed from
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an independent gene: C a, 19pl3.1; Cp, lp36.1; Cy, 9ql3; and PrKX, Xp22.3 (47,48) and
they all exhibit different selective tissue expression. C a is ubiquitously expressed, Cp is
expressed in neuronal tissue, Cy has only been properly identified in the testes, and PrKX is
expressed ubiquitously (4,41,45,46). Human C a and CP share the highest degree of
homology in their primary amino acid sequence (93% identity) and have multiple splice
variants (49-52). C a and Cy are also highly homologous exhibiting 83% identity while Cp
and Cy exhibit 79% identity (45). PrKX shares the least amount o f homology with C a
(53% identity). Activation o f PKA C-subunits is cAMP-dependent. The level o f cAMP in a
cell is controlled through G-protein coupled protein receptors, which stimulate or inhibit
adenylyl cyclase, modulating the synthesis o f cAMP from ATP in response to hormone
agonist (Figure 2) (53). cAMP levels in the cell are also regulated by cyclic nucleotide
phosphodiesterases (PDEs) (Figure 2). PDEs hydrolyze cyclic nucleotides (e.g. cGMP and
cAMP) to 5’-nucleotide monophosphates, eliminating the functional structure o f the second
messenger required to bind to its target (e.g. PKG and PKA). There are 11 known PDE
families (PDE1-11), which vary in their specificities for cAMP and cGMP. O f the eleven
4 cAMP + R2C2 (inactive)
family members, PDE4, 7 and

8

<

4 cAMP*R2 + 2C (active)

(1)

are specific for cAMP. Once cAMP binds the R subunits

(2 cAMP molecules: 1 R subunit), which have a high affinity for cAMP (54-56), the Rsubunits’ affinity for the catalytic (C) subunits decreases by six orders o f magnitude (13).
Thus, at very low levels of cAMP, the steady state favors formation o f the holoenzyme
(Equation 1). In the presence o f increasing levels o f cAMP, the steady state shifts toward
dissociation of the holoenzyme (Equation 1).
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Hormone
CPR
Phosphorylation o f target proteins itahe
membrane and cytosol:
\

’D E 5

P y ru v a te k in a se , R a f 1, A q u a p o rin -2 . . .

\

cAM P

Diffuse to the nucleus to
induce transcriptional
activation:
CREB and CREM

(PKA holoenzym e)

2. PKA intracellular signal transduction pathway. Hormones that
bind G-protein coupled receptors (GCPR) either activate or inhibit adenylyl
cyclase (AC) which generates cAMP, which binds the R-subunits o f the PKA
holoenzyme, releasing the C-subunits, which are now free to propagate the
signal transduction through phosphorylation o f select substrates ( 1 ).
F ig .
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Kinases are catalytic so only a few active kinases are required to propagate a signal for a
given agonist and in most cases the duration o f this activity is transient, lasting for as long as
the agonist is bound to its receptor or that ligand-receptor complex is functional. A disease
state is often associated with deregulation o f a kinase either because the kinase cannot be
activated or inactivated in response to its biological trigger. Determining the role or impact
of PKA on organism development and disease through knock out (KO) models has proven
tricky as there are multiple C-subunit isoforms, thus the KO o f one gene often leads to
compensation by other isoforms. However, 73% of C a KO mice do not survive beyond
weaning, suggesting that this isoform is very important to the organisms development (57).
The remaining 27% that survived did so in part through compensating for the loss of
C a with increased Cp expression, but still suffered from developmental defects (4). While
KO of C a is deleterious in most cases, KO o f Cp has no deleterious effect on mouse
development (58), suggesting that this isoform has a different function from C a and that its
role is not as dominant in the organism’s development. Similar trends are observed with the
R-subunits, where KO of R a isoforms leads to developmental defects and KO Rp isoforms
have little or no impact on the organism’s development (4), but often leads to the onset of
neurological dysfunctions (59,60). These animal models demonstrate that each PKA
isoforms has different functions in the development o f the organism, where C a has a
dominant role in development and Cp has tissue specific functions and compensates for the
loss of the dominant isoforms. Studies o f Cy in KO mice cannot be performed as this is a
primate specific isoform (45). Thus it is difficult to extrapolate from these studies the role
Cy may have in organism development. While KO models have not been used to study
PrKX, it has been demonstrated that PrKX is also important in neuronal differentiation (61).
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Diseases that manifest deregulation o f PKA are rare, but include colon, breast and
prostate cancer (18,62-64), systemic lupus erythematosus (16,17), Cushing’s syndrome
(65), acromegaly, Carney complex (6 6 ), XX male and Swyer’s syndromes (48). What is
observed in cancer is an increase in R-subunit expression (64), which would lead to
increased suppression of C-subunit activity in response to cAMP. This may explain why
extracellular C-subunit is detected in transformed tissue culture cell lines (62) where it is
likely that the cell is trying to compensate for diminished cAMP-response due to the
increase in RI expression by increasing C-subunit expression. This process may continue
until it becomes deregulated. But caution should be exerted when interpreting these results,
as they were preformed with tissue culture cell models where extracellular detection o f the
C-subunit may be due simply to the inadvertent lysis o f a few cells and not to the secretion
of the C-subunit from intact cells, something that has not been properly addressed in the
published work on the subject. Nevertheless, these studies do imply that overexpressed,
cAMP-independent deregulation o f the C-subunit may contribute to the progression of
cancer. Further evidence for this hypothesis is that ectopic expression o f the C-subunit in a
prostate cancer cell line, LNCaP, is sufficient to induce neuroendocrine differentiation
associated with the progression o f prostate cancer (63).
Cushing’s, acromegaly, and Camey complex are endocrine diseases associated with
mutations to R Ia that render expression o f a non-functional R-subunit (67). This mutated RI
subunit would decrease regulation of C a in the cell, making Ca-function cAMPindependent. XX male and Swyer’s syndromes are associated with ectopic recombination of
PrKX in the X and Y chromosomes during development (48), which could lead to the
incorrect expression o f this gene during development. Each o f these diseases clearly
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illustrates that, as with any kinase, the PKA catalytic subunits need to be carefully regulated
within the cell and that deregulation o f this protein has detrimental effects on the organism’s
homeostasis.
PKA

is regulated through transcription,

translation, post-translation and

pseudosubstrates- PKA function is regulated by intracellular levels o f cAMP, but PKA is
also regulated through other mechanisms. The promoters for all the C-subunits are
TATA-less, GC rich promoters with multiple start sites (47), which suggest that
regulation o f these enzymes is under “housekeeping” mechanisms (68,69) associated
with cell and tissue specific expression (70). Expression o f both PKA R- and C-subunits
is also regulated at the mRNA and protein level. C a and CP gene expression is also
regulated through splicing as each has several splice variants, C a l, Cs/Ca2, C p l, Cp2
and Cp3, which are expressed in a cell type selective manner (52,71,72). Unlike C a, CP,
or PrKX, Cy is an intronless retroposon gene that appeared in the human genome forty
million years ago (73), thus Cy is not expected to have any splice variants and makes Cy
the only known example o f a primate specific PKA gene.
The regulation of PKA also occurs through the R-subunits at the mRNA level,
which has been studied selectively in T- and B-cells, sertoli, L 6 myoblast and lymphoid
cells stimulated to undergo cAMP-induced differentiation. RI mRNA is constitutively
expressed in L 6 myoblast cells, thus regulation o f this isoform occurs at the protein level
(74). In T and B cells low levels o f RI-mRNA are observed along with high levels o f RIprotein, and high levels o f RII-mRNA and protein expression are observed suggesting
different regulatory mechanisms for mRNA for each R-subunit isoform in this cell type
(75). Regulation o f RII in sertoli and lymphoid cells differs between R lla and RIip,
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where RIIp mRNA levels do not change between differentiated and undifferentiated
cells, but R lla mRNA levels increase during cAMP-induced differentiation (76-78).
Overall, regulation o f RI expression is favored at the protein level and RII expression
regulation seems to vary depending on the isoform and tissue type.
The R and C subunits are stabilized by formation o f the holoenzyme, as the halflives in the cell for each is twice as long as in the absence of cAMP (in the holoenzyme),
than in its presence (79,80). This suggests that degradation o f the protein by ubquitinmediated pathways is another regulatory mechanism o f cAMP-dependent pathways (74).
Both C and R subunits also undergo post-translational modifications, which modify their
function. RII, but not RI, is phosphorylated at R lla S95 or RII (I SI 12 decreasing its
affinity for the C-subunit (reviewed in (81)). C a is phosphorylated at T197 and
myristylated at glycine 1 (82,83). Phosphorylation on the catalytic loop at C a T197 is a
necessary modification for kinase function, which is conserved among most kinases (84-86).
In the case of C a this modification increases its catalytic activity 100-fold (87).
Myristylation o f C a increases the stability o f the enzyme, as the myristate moiety folds into
a C a hydrophobic pocket, which has the effect o f increasing the protein’s melting
temperature, a measure o f increased stability (83).
Another regulatory mechanism for PKA is through pseudosubstrates, competitive
inhibitor proteins that contain the PKA phosphorylation sequence motif (R-x-x-S/T), but
have an alanine instead o f a serine or threonine and thus cannot be phosphorylated by the Csubunit. The R-subunits and protein kinase inhibitor (PKI) are the two known
pseudosubstrates for the C-subunits. RII is phosphorylated by the C-subunit following
dissociation o f the holoenzyme, so it still serves as C-subunit inhibitor.
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Interaction o f the C-subunits with the R-subunits to form the holoenzyme sequesters
and maintains the C-subunits localized in the cell cytosol ( 8 8 ). In the presence o f cAMP, the
C-subunits dissociate from the holoenzyme. Once released the C-subunits are free to
phosphorylate available substrates in the cell membrane and cytosol and to diffuse into the
nucleus ( 8 8 ) where they can phosphorylate transcription factors (Figure 2) (1). PKI inhibits
and exports the C-subunits from the nucleus terminating its regulation o f transcription
factors (89).
There are several mechanisms by which PKA may regulate multiple cellular
functions- By catalyzing the transfer of the NTP gamma-phosphate to a protein substrate,
the kinase is modifying and altering the phosphoacceptor’s function, propagating and/or
modifying signal cascades within the cell and regulating the cell’s function in response to
extracellular signals (90). Kinases are central to most, if not all, o f the cell’s functions.
Examples o f this include cyclin-dependent kinases, which regulate the cell cycle (91),
receptor associated tyrosine kinases, such as JAK which allow the cell to respond to
interleukins during inflammatory responses o f the immune system (92), and the MAPK
kinase family, one o f the best studied kinase signal cascades which regulate the cell’s
response to growth factors (93). In all of these examples, the kinase is part o f a system
involving ligand (hormones), receptor and effector proteins (kinases), which are able to
regulate multiple cellular functions. Kinases are central to the cell’s ability to function as
both the unit that is the cell and as part of the collective that forms organs and the organism.
With all the variations of this molecule in the human genome the challenge remains to
understand how the kinase is able to function selectively in response to a given stimuli.
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While PKA responds specifically to levels o f cAMP, there are several factors that
give PKA diverse physiological roles. One factor is the presence o f multiple C- and Rsubunit isoforms, which can be expressed ubiquitously or with tissue- or cell-type
selectivity (6,13). This suggests that C- and R-subunit isoforms have specific physiological
roles. Thus, specific functions in the cell can be addressed by either expressing or
activating specific isoforms. Functionally different PKA holoenzymes can be formed and
localized in combinations o f functionally distinct C- and R-subunit isoforms, some of which
have been identified in vivo (5,13,94,95) and provide a potential mechanism to diversity
and/or fine-tune cAMP signal transduction downstream o f the holoenzyme. Such
differences have been characterized between C a and C(3 as pure proteins and in the intact
cell (95,96). Comparative studies have also been done between C a and Cy from partially
purified cell extract (5).
Functionally distinct PKA holoenzymes can be fine-tuned through differential
association o f the varying isoforms to form hetero- or mono-isoform composed
holoenzymes that contain different catalytic or regulatory subunit isoforms within a given
holoenzyme. Thus, not only do the classic Type I PKA or Type II PKA holoenzymes form
in the cell, which contain only RI or RII isoforms, respectively, but also holoenzymes
containing both RI and RII isoforms can form. Such holoenzymes have recently been
observed in T-cells (97). Also, holoenzymes containing multiple C-subunit isoforms were
observed. Thus, multiple C-subunits can be present in a given cellular location within a
given holoenzyme allowing for multiple targets to be phosphorylated with different
specificities in response to a single signal. Or if required, only one C-subunit and or Rsubunit isoform could be present within the holoenzyme, allowing for only one very
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specific response to a given stimuli. What structural differences between PKA C-subunits
would render them such functional differences that would give the cell the ability to
mediate multiple cellular responses through the expression o f different isoforms? Our
hypothesis is that differences between C-subunits may be due to differences in their
primary sequence, which would lead to differences in secondary and tertiary structure
between C-subunit isoforms. This hypothesis will be tested under Specific Aim 1, in
Chapter II, where chimeric constructs will be generated by swapping regions o f low
sequence homology between two C-subunit isoforms and tested for changes in function.
A second factor that may give PKA a diverse role in the cell is its regulation by
other proteins. Proteins known to regulate PKA include protein kinase inhibitor (PKI), Akinase anchoring proteins (AKAP), and phosphoinositide-dependent kinase-1 (PDK-1).
The pseudosubstrate PKI inhibits and exports C a from the nucleus (98) but Cy is
insensitive to PKI (5,13). This is due to specific differences in the amino acid sequence
between C a to Cy (S133Q and Y235F) that form a hydrophobic pocket for PKI-binding
(99,100). Since the R-subunits do not enter the nucleus ( 8 8 ), this raises the question o f what
regulates Cy gene transcription activity in the nucleus.
AKAPs represent another PKA-regulating protein (101). AKAPs bind the Rsubunit and localize PKA holoenzymes in regions where the protein is required. This
leaves the kinase and substrate co-localized in a relatively high concentration, increasing
substrate specificity. As Cy has a lower affinity for R-subunits than C a (102), Cp or PrKX
differ in their affinities for different R-subunit isoforms (46,95), AKAP proteins may not
regulate Cy to the same extent they regulate C a, Cp or PrKX. Furthermore, C a, Cp and
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PrKX localization may be determined through differential associations with the various Rsubunit isoforms.
PKA is also regulated by other kinases (103). In mammalian cells a candidate is
PDK-1, which phosphorylates C a at T197, increasing its catalytic activity (104), but it is
not known if PDK 1 phosphorylates Cp, Cy or PrKX. It is tempting to assume that this
mechanism is conserved across the different C-subunit isoforms as the regions required for
PDK-1 modification o f C a are conserved among all o f them. But this has yet to be
determined experimentally. In the cell PDK-1 does increase the rate o f Cy-mediated
transcription but has little effect on Ca-mediated transcription (105).
Each o f the proteins just described regulate PKA, but with potentially different
effects on the function of each. One o f the most important regulation mechanisms is the
phosphorylation o f C a at T197, which increases its catalytic activity 100-fold (87). It has
not been tested whether this modification is significant for all o f the PKA C-subunits, even
though structural similarities between them suggest it might be. Differential regulation of
this modification among PKA C-subunit isoforms would provide the cell with another
mechanism to fine-tune cAMP-mediated signal transduction pathways. Specific Aim 2, in
Chapter III, will test the significance of this modification to the function o f two PKA Csubunits.
A third factor that may give PKA diverse physiological roles is the kinetic
mechanism of each of the catalytic subunit isoforms. Three of the four catalytic isoforms
(C a, Cp, and Cy) have been shown to vary in substrate specificity as determined through
variance in their catalytic rate constants for the same physiological substrates (20,95). This
suggests that each catalytic subunit may have ‘preferred’ physiological substrates which
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they will modify in response to a given stimuli. This selectivity may allow a given stimuli
to elicit each catalytic subunit to modify different substrates. In addition, the kinetics of
phosphorylation may differ between the isozymes resulting in a temporal difference o f
phosphorylation-mediated activation or inactivation mechanisms that are important to the
sequence o f events regulated by cAMP (12). Specific Aim 3, in Chapter IV, will test if
there is a divergence in the kinetic mechanism o f two PKA C-subunits that could explain
differences in steady-state kinetics for a given substrate.
Together these factors present a model wherein a cell can mediate different
cellular mechanisms in response to the same physiological stimuli through differential
expression, localization, and substrate-specificity by different isoforms o f the same
protein kinase. Characteristics o f this model seem most striking when comparing two
PKA C-subunits that have the greatest divergence in function while maintain relatively
high structural homology, C a and Cy. These two isoforms serve as a simple model for
structure-function characterization o f kinases in order to determine what structural
components in these two C-subunits provides them diverse functions, and how this
translates to functional divergence in other protein kinases.
The conserved structural homology and functional divergence between C a and
C ylend them as an ideal model fo r protein kinase structure-function stu d ies- While both
C a and Cy share 83% identity in primary structure they differ in gene transcription
regulation and substrate and pseudosubstrate specificities (5,20,105,106). Differences in
gene transcription regulation were observed through transient transfections in luciferasereporter assays where C a induced a three to ten-fold higher activation o f CREB-response
elements containing promoters than Cy (105). Differences in pseudosubstrate and
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substrate recognition have been observed where C a is inhibited by PKI while Cy is not
(13,20). Another striking difference between Cy and C a is that while both share similar
Km values (steady-state constant associated with affinity by the enzyme for a given
substrate) for most substrates, suggesting similar affinities, they have very different Vmax
values (steady-state measure o f the enzyme’s reaction rate for a given substrate), with Cy
at least ten-times slower than C a (20). These differences between C a and Cy suggest that
while both enzymes are cAMP-dependent, they may fulfill different functions within the
cell. Unlike C a or C(3, Cy is only found in primates (45,73) and is believed to have entered
the primate gene pool approximately 40 million years ago as a Ca-retroposon (73). Thus Cy
is transcribed as an intronless message and has no known splice variants, as occur for C a or
CP (58,71). Presently the literature considers Cy to be structurally and kinetically
homologous to C a and Cp (e.g. undergoing the same post-translational modifications, such
as myristylation and phosphorylation), when in fact very little is known about the Cy kinase.
Thus, there is a clear need to express and characterize a homogeneous Cy enzyme. However
identification, quantification and characterization o f Cy has been a challenge due to its
apparent low abundance in primate cells and tissues, the difficulty in readily expressing
sufficient levels of the recombinant enzyme, and the absence of Cy-specific antibodies.
Cy is unique to the PKA catalytic subunit isozymes. The Cy mRNA has only been
identified in human testes where it was cloned from a human testes cDNA library (45).
PKA Cs, or C a2, has recently been identified as a testes specific isoform, a splice variant
o f C a expressed in mature sperm (52,107), but unlike Cy this isoform is not human
specific.

Identification of Cy in other tissues has been difficult because o f the high
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homology between Cy and C a and the absence o f isozyme-specific antibodies. One
recent publication describes the identification o f Cy in mouse pancreatic [3-cells through
immunohisotchemistry (108). But this work was done with an antibody that is not
selective for Cy and cross-reacts with other C-subunits (105), and since Cy is not present
in the mouse, it is likely the antibody detected the prevalent isoforms expressed in most
cell lines, C a. The antibody in question was also used to characterize C-subunit
expression in rat cells, where it was reported to identify Cy (a primate specific gene)
(109). Since Cy was originally identified in testes, a tissue with a high a concentration of
cells undergoing differentiation, it is possible that Cy has a function in cellular
differentiation. Furthermore, sperm undergo differentiation that involves specific
isoforms o f the PKA catalytic subunits (52). In addition, Cy is an intronless (45) gene,
and many intronless genes play a role in cellular differentiation (110-116). This suggests
that PKA may have novel role in cellular differentiation through a unique isoform that
has not been described before.
The divergence between C a and Cy function lends these two isoforms as a good
model system to study the effect structural divergence between protein kinases has on
functional differences. Furthermore, studying structure-function differences in vitro and
in intact cells may help further our understanding o f the role and function o f Cy in the
cell. Each of the following chapters (II-IV) will coincide with each o f the specific aims
outlined in this chapter. Chapter V is the result o f work I did in addition to the work
outlined by my specific aims. This work was necessary to demonstrate that Cy was not a
test-tube anomaly, but instead an isoform that has slipped through the cracks o f the PKA
research field, because, as described here in detail, Cy is limited in species expression,
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has proven difficult to isolate and it shares high homology with other isoforms expressed
in the same cell models studied.
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CHAPTER II

IDENTIFY DIFFERENCES IN PRIMARY STRUCTURE BETWEEN PKA-Cy
AND PK A-Ca THAT DEFINE THEIR PHYSIOLOGICAL FUNCTION IN
INTACT CELLS

ABSTRACT
The cAMP-dependent protein kinase (PKA) catalytic subunits C a and Cy share
83% identity in primary structure but differ in gene transcription regulation. The C a
structure has been well characterized, however physical characterization o f Cy’s structure
has not been forthcoming. Both C a and Cy share

86%

identity in their catalytic cores

(amino acids 40-300), 57% identity in their amino terminal (a.a. 1-39) and 83% identity
in their carboxyl terminal (a.a. 301-350). The C a amino terminus is important to
structure stability and the carboxyl terminus is important to substrate recognition by the
kinase. The divergence in homology in the amino and carboxyl terminals makes these
likely regions to be responsible for structure-function differences between C a and Cy.
This hypothesis was tested here with chimera constructs wherein the first 50 and terminal
70 amino acids were swapped between C a and Cy and tested through transient
transfections with CREB-mediated reporter assays. While both wild type (wt) isoforms,
C a and Cy, induced transcriptional activation, the chimera transfections failed to exhibit
any activity in COS7 cells, but exhibited some activity in Kin 8 cells. This difference in
cell-type dependent activity may suggest that there are cell-type specific factors that are
required for the proper expression o f the chimeras. Immunoblot analysis demonstrated
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that each of the chimeras was expressed in COS7 cells and sequence analysis o f the
constructs suggests that the expressed chimeras should have the expected primary
sequence. While it is difficult to interpret the results obtained from the chimera studies,
the amino and carboxyl terminals remain important regions o f divergence between C a
and Cy that warrant further study.
INTRODUCTION
The catalytic subunits for the cAMP-dependent protein kinase (PKA) propagate
extracellular signals through intracellular pathways by phosphorylating protein substrates
at serine or threonine amino acids located within specific sequences (R-x-x-S/T and R-Rx-S/T are two common ones (1)) in response to an increase in intracellular concentrations
o f cAMP. PKA modifies substrates in the membrane, the cytosol, and the nucleus (1).
One of the cellular functions regulated by PKA is gene expression through modification
o f transcription factors in the nucleus such as the cAMP-response element binding
protein (CREB), the cAMP-response element modulator (CREM), and the Nuclear
Factor-KB (NF- kB), or through modification o f transcription factor regulators in the
cytosol such as the NF- kB inhibitor (IkB) (1).
O f the four human PKA catalytic subunits (C a, Cp, Cy and PrKX), the structurefunction differences between C a and Cy are the most striking (5,105). Cy is a putative
retrotranspostion of C a inserted into the human genome some 40-million years ago (73),
which maintains 83% identity with C a in primary sequence but differs in transcriptional
regulation through CRE-containing promoters (5,105). Differences in the transcriptional
regulation range depend on the cell-type used, but Ca-regulated, CREB-mediated
transcriptional activity tends to be 3-10 times greater than that o f Cy (105). There is some
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evidence that Cy may favor transcriptional activity through a different transcription
factor, Spl (105), but this work remains to be corroborated by others. There is
independent work demonstrating that PKA regulates Spl-m ediated transcriptional
activity measured in a human cell line (HL60 cells), however the catalytic subunit(s)
responsible for Spl-mediated transcriptional activity were not identified (117).
As biochemical reactions in the cell follow the structure-equals-function adage, it
is possible that differences in function between C a and Cy can be attributed to
differences in structure. The C a structure has been well characterized through
chrystallography, circular dichroism, and NMR analysis (33,118-120). However, physical
characterization o f Cy’s structure has not been forthcoming because its isolation in
sufficient quantities required for this type o f characterization has proven difficult (20). It
may be possible to predict which regions o f the protein confer C a and Cy functional
differences based on differences in their primary sequence. C a ’s sequence can be divided
into three regions that correspond to structural domains in the folded protein. These
include the amino terminus (amino acids 1-39), the catalytic core (amino acids 40-300),
and the carboxyl terminus (amino acids 301-350) (118,121,122).
C a and Cy share

86%

identity in their catalytic core, which is conserved in most

of the 518 protein kinases in the human genome and has been used as template to define
this region in the protein kinase family (123). The C a amino terminus is important to the
enzyme’s stability and its interaction with the PKA psuedusubstrates. Deletion o f the first
14 amino acids yields a functional isozyme that losses thermostability (a decrease in Tm)
but maintains kinetics similar to wt C a (121). Deleting the first 39 amino acids yields a
non-functional isozyme (121). Interestingly, both isozymes increase the thermostability
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o f the holoenzyme (121). C a and Cy share approximately 57% sequence identity in the
first 40 amino acids, making this a likely region responsible for structure-function
differences between the two isoforms. It is also possible that this region is less important
to the overall function of the enzyme and therefore there can be more variance in the
amino-terminus o f the enzyme, with little effect to the enzymes catalytic function. Nine
o f the first 39 amino acids are not conserved between Cy and C a (at positions

6

, 9, 10,

11, 12, 24, 28, 31, and 34), which constitutes 29% o f the amino acids in this region,
lending credence to the later.
The C a carboxyl terminus is important to substrate recognition by the kinase
(122). Through alanine substitutions four o f the 49 amino acids in this region have been
shown to be important to affinity with ATP (K317, K319, T330, and E332) and six are
important to affinity with the phospho-acceptor substrate (1315, T330, V 3 3 7 ,1339, K345,
and G346) (122). The carboxyl terminal region evidences relatively high homology in
both isoforms (83% identity between C a and Cy), but two residues important to C a
affinity for ATP and Kemptide are mutated in Cy (K319T and V337I), which may be
important to functional differences observed between the isoforms.
Here we decided to test the importance o f the amino and carboxyl terminal
regions to the function o f each isoform, C a and Cy, by generating chimeras o f these
regions. It was hoped that placing either the C a amino or carboxyl terminus on Cy would
confer Cy C a-like functions and that the inverse would hold true for C a. With this in
mind, the first 50 amino acids and the terminal 70 amino acids were swapped between
each isoform and these isozymes were then tested in transient transfections for CREBmediated reporter activity through a reporter vector consisting of a a-glycoprotein
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hormone promoter (which contains two CREB response elements) upstream o f a fire fly
luciferase open reading frame. Unfortunately both the amino and the carboxyl terminal
chimeras were expressed as non-functional proteins, exhibiting a total loss o f
transcriptional activity in COS7 cells relative to the wt isozymes. Loss o f activity was not
due to a lack o f isozyme expression as was demonstrated through immunoblot analysis,
but may be due to numerous other factors that were not tested here. An alternative to the
approach used here would be to express the chimeras for purification and compare their
in vitro kinase activity to that o f the wild type subunits. But this approach defeats the
purpose o f measuring chimera activity through transient transfections, which was to
avoid the complications inherent to protein purification o f an active enzyme, especially
one o f limited stability such as Cy. However, transient transfection reporter assays with
C-subunit chimeras did not address the question as to the significance o f the amino and
carboxyl regions to structure-function differences observed between C a and Cy, but that
does not eliminate the study o f these regions as a potential source for functional
divergence between C a and Cy.
MA TERIALS AND METHODS
Tissue Culture Conditions - Kin 8 mouse adrenal cells were maintained in Hams F-10
media with

10%

heat inactivated horse serum and 1 % neomycin as previously described

(5). COS7 cells were grown in DMEM with 10% FBS. Both cell lines were maintained in
5% C 0 2 at 37°C.
Chimera constructs- The Chimeras were gifts from Wei Qing Zhang, who constructed
both the amino and carboxyl C a and Cy chimera expression vectors (Appendix B).
Primers were ordered through Invitrogen. Sequencing o f chimeras was done in-house
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using BigDye Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems), according to
the manufacturer’s instructions,

on a 3100 Avant Genetic

Analyzer (Applied

Biosystem/Hitoch) automatic sequencer.
Plasmids- pCMV-Ca was a gift from Dr. Michael Uhler (University of Michigan, Ann
Arbor). The pCMV-Cy expression plasmid was created with the addition o f BamHI linkers to
the EcoRI ends of the original Cy cDNA (45) and subcloning the product into the B gll site of
the same pCMV expression plasmid as used for C a. The a-glycoprotein hormone firefly
luciferase reporter plasmid (pGHa-fluc) (124) was a gift from Dr. G. Stanley McKnight
(University of Washington, Seattle). The pCMV-RIIa-GFP expression plasmid used to
determine transfection efficiency was a gift from Dr. Suzan S. Taylor (University of
California, San Diego). A pUC19 vector was used as a filler vector in all transient transfection
experiments.
Reporter Assay Studies- Kin 8 and COS7 cells were added at 325,000 cells per well in 6 -well
plates (9.6 cm /well) (Coming Inc). Cells were allowed to grow for 24 hours to approximately
60% confluence before transiently co-tranfecting with expression, reporter, and/or filler
plasmids. The total amount of DNA loaded into the cell was tested in the ranges o f 0.5-3.0 pg
using FuGENE

6

(Roche Molecular Biochemicals) at a 3 pL Fugene: lp g DNA ratio, before

arriving at the levels described for each experiment. After 24 hours, the transfected cells were
harvested in 500 pL/well of Cell Culture Lysis Reagent (Promega). Firefly luciferase activity
was measured using a Luciferase Assay System (Promega). Briefly, a 100 pL of sample lysate
was added in duplicate wells of a 96-well plate, followed by 100 pL o f firefly luciferase
substrate, luciferin, in “Luciferase Assay Buffer.” The plate was then shaken for 2 seconds and
the number o f photons released measured for

10

seconds using a flash assay setting on an
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MLX Microtiter Luminescence Detection system (Dynex Technologies), recorded in relative
luminescence units.
Immunoblot Analysis - Lysate from samples analyzed by luminometry was assayed with
BioRad’s Protein Assay reagent to determine protein concentration. A total o f 1 pg
protein/transfection condition was loaded in duplicate on a single gel and separated on a
4% stacking, 7.5% running SDS-PAGE gel (125), then transferred to a PVDF membrane
using a semi-dry blotting apparatus (BioRad, according to the manufacturer’s
instructions). The membrane was cut in half and probed with either a rabbit polyclonal
antibody (pAb, Santa Cruz Biotechnology, catalogue # sc903, lot E088, diluted 5000fold), which cross-reacts with both C a and Cy or a rabbit monoclonal antibody (BD
Transduction Laboratories catalogue # 610980, lot

6

, diluted 1000-fold), which

selectively recognized C a, but not Cy. Immunoblots o f chimeras were analyzed using the
pAb to C a. The PVDF membranes were then incubated with a goat anti-rabbit pAb or
anti-mouse pAb conjugated with horseradish peroxidase (Amersham-Pharmacia Biotech).
The membranes were exposed to ECL reagents (Amersham-Pharmacia Biotech) and
imaged on film (Hyperfilm, Amersham-Pharmacia Biotech) or through digital imaging
on a VersaDoc (BioRad).
RESULTS
Chimera Transient transfections- Transfections were carried out in both Kin

8

mouse

adrenal cells and COS7 monkey kidney cells, because wt pCM V -Ca and Cy provide
good reporter assay signals above background (105). COS7 cells are a good model
system for testing Cy because this is the only primate specific catalytic subunit identified
to date (73), and transcription co-factors that may be required to mediate Cy-regulated
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transcription are likely to be present in a primate cell line. Kin 8 cells were used as a
model because they lack any endogenous Cy, thus any differences observed in an in-cell
reporter assay are likely to be due specifically to the ectopic expression o f Cy. Transient
transfections were carried out here using 0.1 pg expression vectors and 0.5 pg reporter
vector, as these concentrations have previously been demonstrated to be optimal in
reporter assay experiments (105). Under these conditions, in COS7 cells, the wt pCMVC a signal was 100-fold above background of a pUC19 empty vector, and the wt pCMVCy signal was ten-fold lower than this signal (Figure 3). This difference in C a and Cy
reporter activity is consistent with previous experiments in COS7 cells (105). The amino
terminal chimeras consisted o f swapping the first 50 amino acids between each C-subunit
and the terminal 70 amino acids for the carboxyl terminal chimeras. Sequencing o f the
chimera constructs demonstrated the expected sequence, however no luciferase activity
was measured in the COS7 cell transfections with the chimera isozymes. Higher
concentrations were tested (0.01-3.0 pg DNA) with no apparent change in the signal
measured (data not presented).
The difference in reporter activity between C a and Cy is not as striking in Kin 8 cells. A
higher amount o f expression vector was necessary to obtain robust signals from
transfections in Kin 8 cells (105), thus all transfections in Kin 8 cells were done with 1.0
pg expression vector. The signal measured for wild type C a was 14-fold lower in Kin 8
cells and about 5-fold lower for Cy (Figure 4), which is only a 3.5 fold difference in
reporter activity between C a and Cy. Furthermore, unlike transfections in COS7 cells,
transfections with amino terminal chimeras in Kin 8 cells did not eliminate all
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3. Transient transfection in COS7 cells with chimeras. Co
transfections with wild type (wt) or chimera expression vectors and
pGHa(CRE4) reporter vector in COS7 cells, n=3, y-axis expressed as Fold
Lums Above Background.
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activity measured from the wt isozymes. There was about a 1.75-fold decrease from wt
C a with the Cy amino-terminal chimera and the Ca-amino terminal chimera activity did
not decrease from wt Cy activity (Figure 4). It should be noted that there was not much wt
Cy activity to begin with (2-fold above background). The carboxyl terminal chimeras
were not tested in Kin 8 cells.
Immunoblot analysis o f chimera transfections in COS7 cells- Extracts from COS7
transfections were analyzed by immunoblot to determine whether the lack o f chimeramediated activity was due to a lack o f expression o f the isozymes during transfection.
Two different antibodies were used selectively to distinguish C a expression from Cy
expression. The first was a polyclonal antibody (pAb) to the carboxyl terminus o f C a that
cross-reacts with Cy. The second was a monoclonal antibody that is selectively
immunogenic against the C a catalytic core and does not cross-react with Cy (105)
(copyright permission for use o f Figure 5A in Appendix C).
Through use of these anotibodies it was demonstrated that C a and Cy proteins
were expressed after eighteen hours (Figure 5A). The polyclonal antibody cross-reacts
with a nonspecific band that is larger than 40 kDa and is present at similar levels in
control cells, where no C-subunit was identified following 18 hours. As the harvest of
transfected cells was done following a 24-hour incubation, the immunoblot demonstrated
that this is sufficient time for the ectopic expression of each isoform. Once it was
established that both wild-type isozymes were being expressed, the polyclonal antibody
was used to measure the expression o f the amino terminal (Figure 5B) and carboxyl
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5. Immunoblot analysis of transfections in COS7 cells. A, shows
the use o f a monoclonal antibody to C a (left panel) or a polyclonal
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transfected with wt pCM V -Ca and pCMV-Cy analyzed at 0 and 18 hours
after transfections (indicated above each lane). B, shows immunoblot of
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with pAb to C a following a 24-hour transfection. Arrows point at the
position o f the catalytic subunit (Cs) and the non-specific band.
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terminal chimeras (Figure 5C) and it appears that the chimera isozymes were expressed
during the 24-hour transfection.
DISCUSSION
Protein folding and its tertiary structure are determined by the sequence o f its
primary structure (126-129) and protein function is dependent on its structure2. Regions
of high divergence between C a and Cy at their amino and carboxyl terminals could
explain functional differences measured between them. Functional differences between
C a and Cy include differential regulation o f CREB-mediated transcription and
differences in steady-state kinetics for physiological substrates. In both instances Cyfunction is less efficient or slower than that o f C a. Differences in transcriptional
regulation can be linked directly to differential regulation o f physiological mechanisms,
as transcriptional regulation is significant to the regulation o f multiple cellular events.
Both C a and Cy are 350 amino acids long and maintain a high degree of
homology throughout the kinase catalytic core (amino acids 40-300,

86%

identity) but

they diverge significantly in primary sequence in the first 40 amino acids (57% identity)
and less so in the terminal 50 amino acids (83% identity). Each o f these three regions is
associated with specific functions for C a. Several approaches could be taken to study the
effect these differences have on C a and Cy function. The approach taken here was to
swap entire sections o f each isoform, generating two new isozymes with the expectation
that placing the Ca-terminals on Cy would make Cy function more like C a and vice
versa. The chimeras were extended slightly beyond the amino and carboxyl terminal
regions, the first 50 instead of 40 amino acids and the terminal 70 instead o f 50 amino

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

36

acids, in part because this was where primers for generating the chimeras would work
best. The homology between C a and Cy does not change significantly with the added
length exchanged between the chimeras. The sequencing o f the chimera constructs agreed
with the expected sequence, thus, based on the sequence, no further alterations to the
protein structure were expected in the products from the chimera expression vectors.
While the wt C-subunit expression vectors behaved as expected in the luciferase reporter
assays no measurable activity was detected from any o f the chimera expression vectors in
the COS7 cells transfections. Chimera transfections in Kin 8 cells did have activity, but in
this cell line the signal o f the wt isoforms was not very robust. Differences in activity
between COS7 and Kin 8 suggests that there may be cell type specific factors that modify
transcriptional activity, but it is not clear why no activity was measured at all in COS7
cells. Sequencing of the expression vectors and immunoblot analysis o f cell lysate
suggests that the protein was being expressed with the correct primary sequence in the
cell. Thus, the difference in activity between Kin 8 and COS7 cell transfection
experiments may be due to factors involved in protein stability. It may be that Kin 8 cells
have better repair mechanisms for misfolded protein than do COS7 cells. If so, this would
suggest that the reason that no activity was measured in COS7 cells was that the chimeras
expressed as miss folded proteins and were not rescued by a mechanism to help re-fold
them properly. However, misfolded proteins are normally found in the insoluble fraction
of cell lysate and the immunoblot analysis o f COS7 cell lysate where the ectopically
expressed C-subunits were identified (Figure 5) were o f the soluble fraction. This would
suggest that the proteins expressed were properly folded. So while the likely explanation

2 “Structure-equals-function” w as our daily chant in B ioch em istry at O ld D o m in io n U n iversity as taught by
M ark E lliott, P h.D .
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is that Kin 8 cells express factors that facilitate the function o f the chimeras, the nature of
these factors is not clear. The approach o f co-expressing the chimeras with protein
chaperons associated with helping in protein folding (reviewed in (130)) could be used to
test this hypothesis.
It may also be possible to trace the degradation o f the chimeras in the cell through
S35-labeling the ectopic proteins and compare the half-lives o f the chimeras to the halflives o f wild-type isoforms when expressed in COS7 and Kin 8 cells. This approach has
been used successfully to measure the half-life o f wt C a in mouse derived cell lines (79).
A shorter half-life for the chimera relative to wt isoforms would suggest that the chimeras
are misfolded and being degraded more rapidly than wt isoforms in the cell (79,131).
Another approach to determine whether the chimeras are not folded properly would be to
isolate the protein (through immunprecipitation) and analyze the protein for structural
differences between wild-type and chimera proteins using circular dichroism, which
would show changes in secondary structure that could be associated with protein
misfolding (119,132-134).
In retrospect, it is possible that the approach utilized here was not the best one to
address structural differences that attribute C a and Cy functional differences in the cell.
A better approach might have been to generate select point mutations throughout the
regions o f interest (the amino and carboxyl domains) that would make one isoform
resemble the other more closely. There are 17 amino acids that are not conserved in the
Cy amino terminus. Each o f these amino acids could be mutated to generate 17
independent isozymes for each isoform. Two more isozymes could be generated, one o f
C a and one of Cy, each containing all 17 o f the mutations. While this approach may not
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work, the modifications made here to each wt Cs isoform in generating the chimeras were
dramatic and the single point mutant approach may allow for the characterization o f the
effect each difference has on the overall enzyme structure and function. A similar
approach has been used to study the C a carboxyl domain, where each amino acid of
interest was mutated to an alanine and each isozyme characterized for function and
stability (122). This approach provided some insight into which amino acids in the
carboxyl group were important to Ca-function. The C-subunit amino terminus still
remains a region o f interest that should be investigated further. This region evidences the
highest divergence in homology and is important to overall protein and holoenzyme
stability.
One problem with characterizing purified recombinant Cy is that it lacks the same
stability as C a (20, 135), so another explanation for differences in function between C a
and Cy may be that Cy is less stable in the cell and therefore less abundant. Differences in
amino-terminal region may also confer on Cy a different tertiary structure than that of
C a. Until studies are done comparing this domain in C a and Cy, it will remain unclear
what effect differences in these regions have on differences in function between isoforms.
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CHAPTER III

CHARACTERIZATION OF PROTEIN KINASE A CATALYTIC SUBUNITS a
AND y PHOSPHORYLATION

ABSTRACT
O f the four human catalytic subunit isoform s- C a, C[l, Cy and PrK X - C a has
been studied extensively and serves as model for all protein kinases but very little is
known about Cy, the only primate specific PKA catalytic subunit. While both Cy and C a
share 83% identity in primary structure, they differ in steady-state kinetics. A striking
kinetic difference between Cy and C a is that, while both share similar Km values for most
substrates, suggesting similar affinities, they have very different Vmax values, with Cy at
least ten times slower than C a. One explanation for the difference observed in their Vmax
is that Cy and C a are not phosphorylated to the same extent. Phosphorylation at T 197 is
key to C a steady-state kinetics, and increases its catalytic rate 100-fold. Experimental
evidence suggests that Cy is either not phosphorylated, or not phosphorylated to the same
extent as C a at conserved residues S139, T197 or S338. Differences in phosphorylation
between C a and Cy were studied here through reporter assays using Cy and C a T197
point mutants, immunoblot analysis using an anti-phospho T197 selective antibody and
LC-MS/MS

phosphomapping

of

purified

recombinant

proteins.

Two

novel

phosphorylation sites were identified on both isoforms by LC-MS/MS analysis (Cy pS14
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and C a and Cy pS259). It was also determined that Cy is phosphorylated homologously
to mammalian expressed C a (pT197 and pS338) and the modification at T197 is
important to the function o f both isoforms, suggesting that differences in posttranslational modification are not the reason for kinetic differences observed between
these two isoforms.
INTRODUCTION
In the human genome 518 kinases are known to exist (2), but few have been
studied as extensively as cAMP-dependent protein kinase (PKA). In the absence of
cAMP, PKA exists as a tetrameric holoenzyme composed of a regulatory subunit dimer
and two catalytic subunit monomers. The regulatory subunits bind cAMP inducing the
release o f the catalytic subunits from the holoenzyme. Once released, the catalytic
subunits are active and able to phosphorylate multiple substrates, propagating
intracellular signals that regulate multiple cellular events (1). O f the four human catalytic
subunit isoform s- C a, Cp, Cy (45) and PrKX (46) - C a has been studied extensively and
serves as a model for all protein kinases (23) but very little is known about Cy, the only
primate specific PKA catalytic subunit (45). While both Cy and C a share 83% identity in
primary structure (Figure
transcription

regulation,

6 ),

they differ in chromosomal location, gene structure, gene

kinetics,

and

specificity

for

peptide

substrates

and

pseudosubstrates (5,20,105,106). A striking kinetic difference between Cy and C a is that
while the two share similar Km values for most substrates, suggesting similar affinities,
they have very different Vmax values, with Cy at least ten times slower than C a (20).
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One explanation for the difference observed in their Vmax is that Cy and C a undergo
different post-translational modifications. C a undergoes several post-translational
modifications, which include myristoylation at glycine

1

(136), deamidation at asparagine

2 (137), and phosphorylation at serines 10, 139, 338 and threonine 197 (82).deamidation
and myristoylation at the amino terminus help stabilize C a (83,119), and phosphorylation
at T197 is key to C a steady-state kinetics (87), increasing the phosphoryl transfer rate
between ATP and the phospho-acceptor 100-fold (138). Experimental evidence suggests
that Cy is either not phosphorylated, or not phosphorylated to the same extent as C a.
Specifically, while both isoforms are approximately 40 kDa, Cy has a smaller Stoke’s
radius than C a and has slower kinetics than C a (20), both o f which agree with
differences observed between phosphorylated and unphosphorylated C a (87,139,140).
Differences in phosphorylation between C a and Cy were tested here using a
CREB-mediated luciferase reporter assay with Cy and C a T197 point mutants, through
immunoblot analysis using an anti-phospho T197 selective antibody, and through
phosphomapping

of

purified

recombinant

hisio-Ca

and

hi 6-Cy

with

liquid

chromatography coupled to tandem mass spectrometry. We found that recombinant Cy is
phosphorylated homologously to mammalian expressed C a, which is phosphorylated at
T197 and S338 (141) and that the modification at T197 is important to the function of
both isoforms suggesting that differences in post-translational modification are not the
reason for kinetic differences observed between these two isoforms.
MA TERIALS AND METHODS
Tissue Culture- All mammalian cells were maintained in 5% CO 2 at 37°C. COS7 cells
were grown in DMEM with 10% FBS and 2 mM L-glutamine. Sf9 insect cells were
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maintained in a spinner flask (BELLCO Glass Inc.) in serum-free ExCell 420 media at
27°C.
Plasmids- pCM V -Ca was a gift from Dr. Michael Uhler (University o f Michigan, Ann
Arbor). The pCMV-Cy expression plasmid was created with the addition o f BamHI
linkers to EcoRI ends o f the original Cy cDNA (45) by subcloning it into the B g ll site of
the same pCMV expression plasmid as used for C a. The a-glycoprotein hormone firefly
luciferase reporter plasmid (pGHa-fluc) (124) was a gift from Dr. G. Stanley McKnight
(University o f Washington, Seattle). The pCM V-RIIa-GFP expression plasmid used to
determine transfection efficiency was a gift from Dr. Suzan S. Taylor (University of
California, San Diego). A pUC19 vector was used as a filler vector in all transient
transfection experiments. The pET16b-hislO-Ca was generated by Sean Collins and was
a gift from Dr. Michael Uhler. Homologous recombination to produce pVL1393-his6-Cy
baculovirus was done as described elsewhere (2 0 ).
Protein Expression and Purification- Recombinant murine hisjo-Ca was expressed from
a pET16b expression vector from IPTG (0.40 mM final) induced BL21(DE3)pLysS
(Novagen) transformed competent cells grown overnight in the presence o f ampicillin
(50pg/mL) at 37°C.

For 1L o f transformed cells (~3g cells), cell suspension was

centrifuged at 11, 500 g (JA14 rotor, Beckman J2-MI), at 4°C, for 2h. The supernatant
was discarded and the cell pellet stored at -80°C. Cells were harvested in 20 mL binding
buffer (50 mM NaPCL, pH [7.9], 0.5 M NaCl, 10% glycerol) with 2 mM PMSF. The cell
suspension was sonicated 5 x

6

sec (mid-setting on a 550 Sonic Dismembrator, Fisher

Scientific), while on ice, with 1 min between sonications. Extract was loaded onto a pre
equilibrated 7 mL Ni-IMAC column (ProBond, Invitrogen) and washed with 10 CV wash
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buffer (binding buffer with 60 mM imidazole). Initially the enzyme was eluted with an 80
mL 0.06-1.0 mM imidazole gradient in binding buffer, while collecting 1 mL fractions,
with the elution peak at about 350 mM imidazole, followed by separation on a Sephadex
S300 gel filtration column. It was subsequently found that similar results were obtained if
the protein was eluted with a 20 mL 0.06-1.0 mM imidazole gradient off a 2 mL NiIMAC column, while forgoing the gel filtration step (while loading the same amount of
cell

lysate).

Both

approaches

provided

about

5.5

U/mg

o f pure

hisio-Ca.

Unphosphorylated hisio-Ca was obtained by expressing pET16b in BL21(DE3)pLysS
cells in the presence o f membrane permeable, Ca-ATP inhibitor H89 (100 pM final, 10
mM stock in DMSO) and purified through Ni-IMAC chromatography.
For protein expression and purification o f human his 6-Cy, Sf9 cells were grown to
70% confluence in spinner flasks (approximately 2 xlO 6 cells/mL in 1L o f growth
media), infected with his 6 -Cy-baculovirus (80 pfu/cell) and incubated for three days at
27°C. Infected Sf9 cells were centrifuged (1,500 x g for 5 min) and the pellets stored at 80°C as 500 xlO 6 cell/aliquots. Aliquots were homogenized in 15 mL binding buffer (50
mM K P 0 4, pH [7.9], 250 mM KC1) with 2 mM PMSF using a ground glass dounce
homogenizer (Pyrex). The homogenate was centrifuged (15,800 x g for 30 min at 4°C)
and the supernatant was applied to a 15 mL Ni-IMAC column (=3xl0 7 cells/ml resin).
The column was washed with 3 CV o f binding buffer, 10 CV o f wash buffer (binding
buffer with 60 mM imidazole) and eluted with an 80 mL 60-600 mM imidazole gradient
in elution buffer (binding buffer adjusted to pH [6.4]), while collecting 1 mL fractions.
Fractions were assayed for kinase activity. Fractions exhibiting the highest specific
activity were pooled and concentrated with Amicon U ltra-15 Centrifugal Filter Devices
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(Millipore, 10, 000 MWCO). The protein peak elution occurred at ~ 350 mM imidazole.
The purified protein had a SA o f 0.5 U/mg and was analyzed for purity by SDS-PAGE
subjected to silver staining, coomassie staining, or Sypro Ruby Staining (Molecular
Probes).
Point M utants- Site-directed point mutants T197D and T197A were incorporated directly
into pCM V-Ca and pCMV-Cy expression vectors using QuickChange II XL site directed
mutagenesis kit, according to the manufacturer’s instructions (Stratagene). Primer
sequences used for point mutants are shown in Table I. Sequencing o f point mutants was
done using BigDye Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems),
according to the manufacturer’s instructions, on a 3100 Avant Genetic Analyzer (Applied
Biosystem/Hitoch) automatic sequencer.
Reporter Assay Studies- COS7 and Sf9 cells were added at 325,000 cells per well in 6 well plates (9.6 cm 2/well) (Coming Inc). Cells were allowed to grow for 24 hours to
approximately 60% confluence before transiently co-transfecting with expression,
accessory, reporter, and/or filler plasmids (0.5-3.0 pg total DNA range) with FuGENE

6

(Roche Molecular Biochemicals) using a 3 pL Fugene: 1pg DNA ratio. After 24 hours,
the transfected cells were harvested in 500 pL/well o f Cell Culture Lysis Reagent
(Promega). Firefly luciferase activity was measured using a Luciferase Assay System
(Promega). Briefly, 100 pL o f sample lysate was added in duplicate wells o f a 96-well
plate, followed by 100 pL o f firefly luciferase substrate, luciferin, in “Luciferase Assay
Buffer.” The plate was then shaken for 2 seconds and the number o f photons released
measured for

10
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I
Primer Sequences used fo r Point Mutants
Table

Mutant
CyT197D
CyT197A
CaT197D
CaT197A

Forward
GGGCCGCACTTGGGACT
TGTGCGGGACC
GCCGCACTTGGGCCTTGT
GCGGGA
AA AGGCCGT ACTTGGGA
CTTGTGTGGGACCCC
GGCCGTACTTGGGCCTTG
TGTGGGAC

Reverse
GGTCCCGCACAAGTCC
CAAGTGCGGCCC
TCCCGCACAAGGCCCA
AGTGCGGC
GGGGTCCCACACAAGT
CCC AAGT ACGGCCTTT
GTCCCACACAAGGCCC
AAGTACGGCC
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seconds using a flash assay setting on an MLX Microtiter Luminescence Detection
system (Dynex Technologies) and recorded in relative luminescence units. To determine
transfection efficiency control, cells were co-transfected with 0.5 pg pCMV-RIIa-GFP,
incubated 24 h, trypsin treated, and mounted on a slide (centrifuged at 7.06 g, 7 min on a
Shandon Cytospin III centrifuge). Transfection efficiency was determined as a percent by
the ratio o f fluorescent cells counted under fluorescent light over total cells counted under
white light in the same field (xlOOO magnification, under oil emersion, on a Ziess
Axioscope fluorescent microscope). A minimum o f 200 cells/transfection experiment
were counted.
Immunoblots- Samples were separated in a 9% SDS-PAGE gels with a 4% stacking gel,
transferred and treated with antibodies as described previously (105). Three different
antibodies were used: a rabbit polyclonal antibody to C a, which detects both C a and Cy
(Santa Cruz Biotechnology sc-903, 1:1000); a rabbit monoclonal antibody to phosphoT197, which was a gift from Dr. Alexandra Newton’s laboratory at the University of
California at San Diego (p500 antibody, 1:1000, generated by Dr. Joanne Johnson
(142,143)); and a rabbit polyclonal antibody to PICA substrate phospho-serine\threonine
(Cell Signaling, cat # 9621, 1:1000). Following primary antibody treatment and washes,
the membranes were incubated with HRP-conjugated anti-mouse or anti-rabbit
polyclonal antibodies (Amersham Biosciences, 1:1000), then washed. The membranes
were developed using Immun-Star HRP substrate (BioRad) and imaged electronically
(BioRad’s VersaDoc imaging system).
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Sf9 cells were harvested to determine PDK1 expression (10 mM potassium
phosphate pH [6.9], 1 mM EDT, 0.5% triton-X 100 and 2 mM PMSF). PDK1 expression
was measured with a rabbit polyclonal antibody (Cell Signaling cat # 3062, 1:1000).
Kinase assay- In a standard kinase assay, the activity o f the C-subunits was determined
by the transfer o f y-32'P-ATP (200 pM) to peptide (65 pM Kemptide, LRRASLG) in the
presence and absence o f the protein kinase inhibitor peptide (amino acids 5-24) PKI 5-24 (2
pM), as previously described (5). Briefly, a 50 pL reaction mixture contained 30 pL test
mix (50 mM Tris-HCl (pH 7.0), 200 pM ATP, 20 mM magnesium acetate, 10 mM DTT,
and y32P-ATP (300 cpm/pmol)) plus 10 pL substrate. The reactions was initiated with the
addition of 10 pL o f the enzyme and incubated at 30°C for ten minutes, spotted on P-81
paper, and placed in 75 mM phosphoric acid to terminate the reaction. The strips were
washed in phosphoric acid 4-5 times, for ten minutes each wash, washed once in ethanol
and allowed to dry before being placed in liquid scintillant. Specific activity
measurements were incubated for 2, 4, 6 , 8 , and 10 minutes.
To measure phosphorylation o f Cy by a PKA kinase, 128 nmoles his 6 -Cy were co
incubated with 0.01 U his-PDKl (Upstate) in a standard kinase assay using kemptide as a
Cy-substrate. Cy activity was measured at regular intervals over a 30-minute time course.
PDK1

activity

was

determined

in

a

separate

experiment

using

PDKtide

(KTFCGTPEYLAPEVRREPRILSEEEQEMFRDFDYIADWC, Upstate) as a substrate in
a standard kinase assay.
Phosphopeptide mapping and analysis- Protein bands were excised from polyacrylamide
gels. Gel slices were cut into 1-2 mm cubes, washed 3 X 500 pL Ultra-pure H 2 O, and
incubated in 100% acetonitrile for 45 minutes. If the gel was silver stained, the stain was
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removed

with

SilverQuest™

destaining

solution

following

the

manufacturer’s

instructions. The material was dried in a speed-vac and rehydrated in 12.5 ng/pL
modified sequencing grade trypsin solution (Promega) and incubated in an ice bath for
approximately 45 minutes. Excess trypsin was removed and replaced with 40 - 50 pL of
50 mM ammonium bicarbonate, pH 8.0. Proteins in solution were digested using the
ProteoExtract™

Trypsin

digest

kit

(Calbiochem)

following

the

manufacturer’s

instructions, with the exception that Promega trypsin was used instead o f the trypsin
provided with the kit. All trypsin digests were allowed to proceed overnight at 37°C.
Peptides were then extracted 2X with 25 pL 50% acetonitrile, 5% formic acid, then dried
in a speed-vac, and resuspended in 20 pL Buffer A (5% Acetonitrile, 0.1% Formic Acid,
0.005% heptafluorobutyric acid (HFBA)). Digests (3-6 pL) were loaded onto a 12-cm X
0.075 mm fused silica capillary column packed with 5 pM diameter Magic™ C-18 beads
(The Nest Group, Southboro, MA) using a N 2 (g) pressure vessel at 1100 psi. Peptides
were eluted by applying a 55 or 150 minute, 0 - 80% linear gradient o f Buffer B (95%
Acetonitrile, 0.1% Formic Acid, and 0.005% HFBA) at a flow rate o f 130 pL/min with a
pre-column flow splitter, resulting in a final flow rate o f -2 0 0 nL/min directly into the
source. The LCQ-DecaXP (Thermofinnigan) was run in automatic collection mode with
an instrument method composed o f a single segment and four data-dependent, scanned
events with a full MS scan, followed by 3 MS/MS scans of the highest intensity ions.
Normalized collision energy was set at 30, activation Q was 0.250, with the minimum
full scan signal intensity set at 5 X 105 and a minimum MS2 intensity at 1 X 104.
Dynamic exclusion was turned on utilizing a three-minute repeat count o f 2, with the
mass width set at 1.50 Da. Sequence analysis was performed with Sequest™ using an
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indexed human subset database o f the non-redundant protein database from NCBI (PKACy accession number: NM_002732, PK A -C a accession number: NP_032880).
Protein Phosphatase Treatment- Samples containing 50 pmol (2 pg) pure hisio-Ca were
incubated with 0.75 U o f bovine kidney PP2Ai (0.5 pg, >90% pure, Sigma) in 50 pL
reaction buffer (20 mM Tris-HCL, pH [7.5], 2 mM MgCE, and 1 mM DTT) at 37°C for
30 minutes. The reaction was quenched with 20% Trifluoroacetic acid. Spin-Out™ GT600 desalting columns were used to replace the reaction sample buffer with 50 mM
Ammonium Bicarbonate, pH [8.0]. Samples were digested as described above.
RESULTS
Effect o f Point Mutants on the C-subunit’s function- It has previously been shown that
COS7 cells are optimal for comparing C a and Cy-mediated reporter activity through
CRE-containing promoters, such as the a-glycoportein promoter (105). Sf9 cells were
also used as a model because they are the same cell line from which recombinant Cy is
purified (20). Dose response studies with 0.5 pg pG fta-fluc and 0.01-1.0 pg pCM V-Ca
wt and pCM V-Ca T197D determined that 0.1 pg and 1.0 pg were the most effective
doses for transfections with Fugene6 in COS7 and Sf9 cells, respectively (data not
shown) with a transfection efficiency o f 22 ± 5 % (average ± standard deviation)
(Appendix D). Ectopic expression o f pCM V -Ca wt provides a robust signal through the
pG H a-flue reporter vector (78-fold above background) in COS7 cells and a weaker
signal in Sf9 cells (3.5-fold above background) (Figure 7). The C a T197A point mutation
knocks out 98% o f pCM V -Ca wt mediated reporter activity (3-fold above background) in
COS7 cells and 25% o f activity in Sf9 cells. Some 13% o f pC M V -C a wt activity is
restored with the C a T197D point mutant in COS7 cells and 10% activity is restored by
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this mutant in Sf9 cells. As previously reported (105), ectopic expression o f pCMV-Cy wt
mediated pG H a:/7woactivity was about 52% and 33% lower than that o f pCM V -Ca wt
in COS7 and Sf9 cells respectively (37-fold and 2-fold above background respectively).
However similar trends were observed with the pCMV-Cy point mutants, with Cy T197A
mutant knocking out all activity and T197D restored activity back to pCMV-Cy wt levels
in both COS7 and Sf9 cells. Although not shown here, cell density affected Cy-mediated
reporter activity, where at high cell density levels(>80% confluence) little or no reporter
activity was measured in the presence o f Cy in both cell lines tested here. This
observation did not hold true for C a transfections.
Effect o f PKA Kinase on Recombinant Cy- C a is phosphorylated at T197 through
autophosphorylation in prokaryotic cells (140,144) and through another kinase in S49
mouse lymphoma cells (103). Studies done in the intact cell and in vitro suggest that
phosphoinositide-dependent kinase-1 (PDK1) is a candidate for physiological regulation
of PKA (86,104,145). As recombinant Cy is expressed in and purified from a eukaryotic
cell line (Sf9 cells) it is possible that Cy has low activity because this cell line lacks a
PDK1 homologue to phosphorylate Cy and Cy may not be able to autophosphorylate. To
determine whether Sf9 cells expressed PDK1, Sf9 cell extract was tested through
immunoblot analysis using a polyclonal antibody to PDK1 (Figure 8). The antibody
detected a band doublet o f which the major band had an apparent MW o f 63 kDa (as
determined through extrapolation of its R/) that coincides with the MW reported for
PDK1 (146,147). The band doublet may represent two different PDK1 isoforms
expressed in this cell line or two different modification states o f the same isoform.
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F ig . 7 . T197 point mutant transient transfections demonstrate its
importance to ca and cy function. Co-transfection of p G H a-flue with pCMVCs wt, pCMV-Cs T197D and pCMV-Cs T197A in A, Sf9 cells and B, COS7
cells using 0.1 pg or 1.0 pg expression vector, respectively. Values are expressed
as fold above background (transfections with pUC19).
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F ig . 8 . Immunoblot analysis of Sf9 cell extract identifies an
immunoreactive band. Pure recombinant his6-PDKl (40 ng o f truncated
PD K I 52 -556 , at left), Sf9 cell extract (5.8-174 jag, upper panel) and
GAPDH (loading control) were run on a 9% gel and analyzed with an
anti-PDKl rabbit polyclonal antibody. The apparent molecular weights
o f each band are indicated by the arrows to the right o f the gel.
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Purified PDK1 was co-incubated with recombinant Cy in a standard kinase assay to test
whether PDK1 could modify Cy activity (Figure 9A). It was found that Cy steady-state
activity did not change in the presence o f PDK1 suggesting that purified recombinant Cy
is already phosphorylated at T197. PDK1 activity was tested independently with a PKB
based peptide substrate, PDKtide, and Kemptide and demonstrated to be active and to
have about three fold higher activity with PDKtide (Figure 9B).
Measurement Phosphorylation through Immunoblot Analysis- Immunoblot analysis o f
both purified isoforms was used to directly measure C-subunit phosphate content.
Phosphate content was tested through the use o f two antibodies, one that specifically
detects phosphorylation at T197 (142,143) and a second antibody that detects
phosphorylation at arginine-directed serines or threonines (R-directed Ab), such as the
PKA phosphorylation consensus sequences (R-x-x-S/T). Figure 10 shows that both
antibodies detect phosphorylation in both pure C a and Cy, and C a expressed in the
presence o f H89, a membrane permeable inhibitor that selectively binds the C-subunit
ATP binding site, was not phosphorylated. The absence o f phosphate on Ca(H89)
supports the mechanism o f autophosphorylation for E. coli expressed C a. Both
antibodies detect phosphorylation at T197, but the R-directed Ab may also detect
phosphorylation at the other sites on both isoforms. C a expressed in E. coli is reported to
be phosphorylated at four residues, S10, S139, T197 and S338 (140), but phosphorylation
o f Cy has not previously been studied.
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F ig . 10. Immunoblot analysis of pure C a and Cy identifies both isoforms
as phosphoproteins. Pure C a expressed ± H89 and Cy were analyzed with A,
anti-C a rabbit polyclonal antibody, B, anti-RxxpS/T antibody, or C, p500
antibody, which is specific for phosphorylation at T197.
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LC-M S Phosphomapping o f the Catalytic Subunits- Both recombinant isoforms were
subject to LC-MS/MS analysis to identify which residues were phosphorylated. Criteria
for considering a peptide to be phosphorylated included identification by MS/MS of
known phosphorylation sites on C a, identified peptides must have >70% o f the b or y
ions series, the phosphorylated peptide must have been seen in at least two independent
runs, and the total number o f ions present for a given scan need to be low enough such
that the probability o f randomly assigning ion masses is statistically negligible. Three
forms o f C a were analyzed: (1) native C a, (2) C a treated with PP2A and (3) C a
expressed in the presence o f H89, a C a competitive inhibitor that binds the Ca-ATP
binding site and blocks Ca-autorphosphoryation when C a is expressed in its presence.
What was expected in this experiment was the identification and then subsequent removal
o f phosphates from Ca.
Three phosphopeptides were identified on recombinant C a by MS/MS base peak
neutral loss analysis (Figure 11). The phosphorylation position on the peptide was
identified by manual spectral analysis at KgGpSEQESVKEFLAK2i (790.9 m/z) for S10
(49 m/z loss), I 135GRFPSEPHAR 144 (1170.32 m/z) for S139 (98 m/z loss), and
G 193RTWPTLC 199 (894.04 m/z) for T197 (98 m/z loss) (Figure 11). Incubating C a with
PP2A resulted in phosphate removal only at S139 (Figure 11B) and Ca(H89) lacked
phosphates at all three sites (Figure 11C). Base peak neutral loss chromatograms were
normalized (NL) to base peak amplitude and a decrease in signal was observed between
conditions (C a wt NL = 1.21 x 109, Ca(PP2A) = 8.1 x 108, C a(H 89) = 7.66 x 105).
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There may have been removal o f phosphate at T197, however our approach was not
quantitative, thus we could only measure the presence or absence o f a phosphate.
Subsequent scans using a longer gradient (150 min 0-80% buffer B) identified phosphates
at V 337PSINEKCGKEFTEF 350 (1711.8 m/z, Xcorr= 1.8, ACn= 0.5) for S338 and at
F 257PpSHFSSDLK 266 (1245.3 m/z, Xcorr= 1.9, ACn= 0.2) for S259.
Mapping o f Cy identified phosphopeptides at four distinct sites:
D 8TEQEEpSVNEFLAK 2 1 (820.41 m/z) for S14 (Figure 12),
Ti95WpTLCGTPEYLAPEIILSK2i3 (1144.309 m/z) for T197 (Figure 13),
F257PpSKLSSDLK266 (601.86 m/z) for S259 (Figure 14), and
Y3l6TGPGDASNFDDYEEEELRIpSINEK342 (1487.069 m/z) for S338 (Figure 15).
Phosphorylation at Cy SI 39 was not identified in any o f the LC-MS/MS runs performed.
However, identification o f phosphorylation at S259 on both isoforms is a new
observation. Phosphorylation at C a S14 was not identified in any o f the runs.
DISCUSSION
Autophosphorylation is an important mechanism for regulating protein kinases (81).
Escherichia coli expressed PK A -Ca autophosphorylates at four residues, S10, S I39,
T197, and S338 (140) which are phosphatase resistant (141,144). Eukaryotic expressed
C a is phosphorylated at T197 and S338 by a PKA kinase (148) o f which pT197 can be
removed by a PP2A-like phosphatase in S49 cells (148). However, phosphatase removal
o f pT197 is enhanced under denaturing (148) and oxidation conditions (149), suggesting
that this is a very stable modification. Analysis o f the Cy Stoke’s radius, in gel apparent
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F ig . 14. LC-MS/MS scan of phosphopeptide F 257 PPSKLSSDLK 266 from
recombinant PKA-Cy trypsin digest. Parent ion for phosphorylation at Cy
259. m/z 601.86 12+1.
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molecular weight and steady-state kinetics suggest that unlike C a, Cy may not be
phosphorylated (20).
Characterization o f PKA phosphorylation had previously been done through
tryptic digest-analysis o f P32-labeled enzyme, mass spectroscopy, analytic isoelectric
focusing and chromatography analysis (139). Only recently has liquid chromatography
coupled to tandem mass spectroscopy (LC-MS/MS) technology been successfully used to
identify phosphorylation sites on recombinant C a (150), but such characterization had
not been tried with Cy in part because its expression and isolation has been a challenge
(20). Recombinant Cy expresses as an insoluble protein in E. coli, but can be expressed in
eukaryotic cells including murine Kin8 cells (5) and insect Sf9 cells (20). Both
expression systems provide a low yields relative to C a expressed from E. coli, and once
pure the Cy half-life at -80°C or in liquid nitrogen is much shorter than that o f C a
(months vs. years at -80°C). Recombinant his-Cy has been expressed here to ease its
purification and characterization. This approach allowed for sufficient Cy to be purified
for its characterization through immunoblot and LC-MS/MS analysis.
Two o f the four C a putative phosphorylation sites, T197 and S338, were
identified on Cy via LC-MS/MS and immunoblot analysis, while phosphorylation at all
four putative sites was identified on C a. Two novel modifications were also identified on
Cy at S14 and at S259 on both isoforms. The modification at Cy S14 may be analogous to
phosphorylation at C a S10, which is not conserved in Cy (Figure 6). The sequence
surrounding Cy S14 (QEESV) does not fit a PKA phosphorylation site but was identified
as a potential casein kinase 2 (CK2) phosphorylation sequence (OMIGA software). Since
Sf9 cells contain a CK2 homolog (151) this modification may be an artifact o f expressing
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Cy in Sf9 cells. However, CK2 is present in all eukaryotes, so it is also possible that
phosphorylation at this residue is important to Cy function and that this modification is
present on Cy expressed in human tissue and Cy ectopically expressed in murine Kin8
cells. The function o f phosphorylation at C a S10 is still not clear (119) therefore it is
difficult to speculate what difference phosphorylation at S14 instead o f at S 10 will have
on the enzyme’s function. Phosphorylation at S259, which was observed on both C a and
Cy, may also be an artifact o f overexpressing a recombinant protein and may not have
any biological relevance. Such is the case for modifications on C a S10 and S I39, which
are only observed on C a expressed in bacteria, yet have no known biological function.
Since this modification has not been previously described for C a it may not be that C a is
not abundantly modified at S259 and thus the modification is only present on a small
fraction o f the enzyme purified and thus not detected until now. There are at least three
major isozymes o f recombinant C a identified from E. coli expression that are distinct in
the number o f phosphates each contains (2, 3, and 4) (139), but there is some evidence
that suggests the presence o f more (personal communication from Drs. Suzan Taylor and
Mike Deal).
The fact that both isoforms purified from different expression systems contain this
modification suggests that the mechanism for phosphorylation at S259 may be the same
on both enzymes. The sequence surrounding S259 (RFPS) agrees with a PKA
phosphorylation

sequence (R/KxxS/T

(1)) but was also identified as a PKC

phosphorylation site (OMIGA software). Since the modification occurred in both
prokaryotic and eukaryotic cells it likely that phosphorylation occurred through an
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autphosphorylation mechanism for which there is a precedent in E. coli expressed C a
(140,144,152).
Modifications to S10 and S I39 were not identified on Cy. Myristylated C a
exhibits reduced phosphorylation at S10 and S I39 (82), however it remains to be
determined if Sf9 expressed Cy is myristylated. Identification o f phosphorylation to C a
S139 has been problematic for others (150) yet C a pS139 was one o f the first
modifications identified here. This discrepancy may stem from differences in expression
conditions which may lead to differences in the phosphate content in the isozymes
expressed (153). Phosphorylated C a S139 was identified here by base peak neutral loss
analysis and found to be the only phosphate completely removed by PP2A, suggesting it
is a very labile modification relative to phosphorylation at T197. Phospho-T197 may
have only been partially removed by PP2A and therefore not observed by LC-MS/MS
analysis.
Sf9

expressed

Cy contains

phosphorylation

modifications

analogous

to

mammalian expressed C a (141). The mechanism for phosphorylation o f Cy is not known
at this time, but it may be through PDK1, a known PKA kinase (86,104,145). Since C a is
a PDK1 substrate in eukaryotic systems and both C a and Cy share sequence homology at
three o f the four putative phosphorylation sites (Figure 6) and Cy contains the PDK1interacting fragment (F-x-x-F), located at the C terminus of the PDK1 substrate (154), it
is likely that Cy also serves as a PDK1 substrate. An immuno-reactive 63 kDa band was
identified in Sf9 cells suggesting PDK1 is present in this cell line making PDK1
phosphorylation o f Cy T197 a likely mechanism. Phosphates on C a are very stable as
they are not easily added or removed once the kinase is translated (139,140,144) which
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may explain why co-incubation o f PDK1 did not increase Cy steady-state kinetics. Since
Sf9 cells express endogenous C a it is also possible that C a phosphorylates Cy. Bacterial
expressed Cy, like C a (T197A), is insoluble and inactive (20,87) so it was thought that
co-expression o f C a and Cy may increase Cy stability, however this was tested and found
not to be true (data not shown), suggesting that either E. coli expressed Cy is already
phosphorylated or that C a cannot modify Cy.
The use o f point mutants here

demonstrated that phophorylation at T197 is

important to Cy function. The T197A point mutant makes the site inaccessible to
modification and is deleterious to C a and Cy mediated transcriptional activation while
the T197D mutation, which mimics phosphorylation at this site, restores some (C a) or all
(Cy) of the lost activity. Cell-type differences were observed in the amplitude o f the
reporter signal measured between COS7 and Sf9 cells for C a and Cy transient
transfections. In both cell lines Cy-mediated reporter activity was lower than that o f C a
as has been reported elsewhere (105) but Cy-mediated reporter activity was higher in
COS7 cells than in Sf9 cells. This difference may be due to differences in the cellular
protein profile and in the regulation o f the C-subunit isoform. While Cy expressed from
Sf9 cells is phosphorylated at T197, it may be that modification o f the catalytic subunits
is more efficient in mammalian COS7 cells than in insect Sf9 cells or that Sf9 cells have
efficient phosphatases not present in COS7 cells.
While recombinant Cy is phosphorylated at T197 and this modification is
important to the isoforms function the question still remains as to what causes the
functional differences observed between C a and Cy. Another possibility is that sequence
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differences in the C a and Cy amino and carboxyl termini (Figure 6) contribute to
functional differences measured between them. Studies done with C a and Cy amino and
carboxyl terminal chimers resulted in the expression o f non-functional isozymes in COS7
cells. However, the amino terminal chimers had little effect on their function when
expressed in Kin8 cells (Chapter II). Another possible explanation for functional
differences between C a and Cy may be in the binding and release rates o f the nucleotide
substrates. The release o f ADP is the rate-limiting step for C a (34,35). It may be that
overall structural differences between C a and Cy induce differences in the rate o f the
rate-limiting step. This hypothesis is explored in Chapter IV.
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CHAPTER IV

CHARACTERIZE THE KINETIC MECHANISM FOR PKA C a AND Cy
THROUGH DETERMINATION OF THE RATE CONSTANTS FOR EACH
CATALYTIC STEP OF THE PHOSPHOTRANSFERASE REACTION

ABSTRACT
Human PKA catalytic subunits C a and Cy share high homology in their primary
structure (83% identity) but differ in biochemical function. The hypothesis explored here
is that C a and Cy differ in their catalytic mechanisms, possibly in their substrate bindingrates, and that differences in their mechanisms translate to differences in their
biochemical function. To this end recombinant C a nucleotide binding rates were
determined and compared to the Cy ADP off-rate through stopped-flow analysis, using
mant-ATP and mant-ADP. The Ca-A TP on and off rates were determined (1.6 x 106 M '1
s’1 and 174 s '1 respectively) and found to be in good agreement with the literature. The
C a ADP dissociation rate (33 s '1) was slower than the ATP on-rate at physiological ATP
concentrations, which suggests that ADP release is the rate-limiting step. However, a
second slower rate was measured for mant-ATP binding (19 s '1), which may suggest that
mant-ADP dissociation is not the rate-limiting step. Recombinant his6-Cy was used to
measure its mant-ADP-off rate, a step where divergence in the catalytic mechanism from
C a could explain differences in biochemical function. The signal measured for the Cy
ADP off-rate was reproducible but very low (4 s '1). The measured A DP-off rate for C a is
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about 9-times faster than that o f Cy, a result that is in agreement with differences in their
steady-state kinetics. The physiological ramifications o f biochemical difference between
C a and Cy still needs to be determined through studies o f the isoforms in vivo and in the
intact cell.
INTRODUCTION
Human PKA catalytic subunits C a and Cy share high homology in their primary
structure (83% identity) but differ in their function. Differences include CREB-mediated
transcription

regulation

and

steady-state

kinetics

(5,105),

where

Ca-regulated

transcriptional activation is 3-10 times higher than that o f Cy and Cy-steady-state kinetics
are 10-times slower than that o f C a for most substrates tested (20). It is o f interest to
establish what factors contribute to these differences, which may manifest themselves
physiologically. Several approaches have been attempted with little success to elucidate
structural differences between C a and Cy that could be responsible for their functional
differences (Chapters II and III). The hypothesis explored here is that C a and Cy differ in
their catalytic mechanisms, either in their substrate binding-rates or product dissociation
rates, and that differences in their mechanisms translate to differences in their
biochemical function.
The C a catalytic mechanism has been well characterized through stopped-flow
analysis, viscosometric analysis, characterization o f point mutants and steady-state
kinetic characterization (34,87,155,156). The mechanism is described as a sequential or
ordered Bi-Bi mechanism (Figure 16) where ATP binds PKA first, causing a
conformational change that allows for the binding o f the phosphoacceptor, followed by
an associative, inline transfer of the y-phosphate from ATP onto the acceptor (reviewed
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in (157)). Once phosphorylated, the phospho-substrate is released, followed by the
release o f ADP, which has been proposed to be the rate-limiting step o f this mechanism
(34). Here it was decided to compare recombinant C a and Cy binding rates for ATP and
ADP because the binding rates o f the phospho-acceptor substrate vary depending on its
nature and proper progression o f the reaction depends on ATP binding the active site
before the phospho-acceptor (Figure 16). The proper binding order o f the substrates is
important to the progression o f the catalytic mechanism as illustrated by the fact that
when the phospho-acceptor binds C a before ATP the enzyme becomes locked-up in this
species (Ca-S-ATP) and contributes little to the total phospho-substrate (p-substrate)
generated (157) (Figure 16).
Analysis o f the C a and Cy catalytic mechanism was done here through stoppedflow analysis, using ATP and ADP conjugated to a N-methylanthraniloyl (mant)
fluorophore through the ribose ring (Figure 16). This fluorphore is smaller than most
flurophores decreasing the perturbation in the enzyme reaction. Furthermore the
absorption and emission properties o f mant are distinct from those o f proteins and nucleic
acids, has a long fluorescent halve-life, and has high sensitivity to small changes in its
environment.
Using stopped-flow the Ca-ATP on and off rates were measured and found to be
in good agreement with the literature (155). The homogenous purification o f recombinant
his6-Cy proved to be difficult, but enough was attained to measure the Cy ADP-off rate, a
step where divergence in the catalytic mechanism o f these two isoforms could explain
differences in biochemical function
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SUBSTRATE
ATP
P - SUBSTRATE

C - ATP SUBSTRATE

C - ADP I
P - SUBSTRATE

i

ADP

SUBSTRATE

F ig 16. Diagram depicting the Cleland shorthand notation for the C a
catalytic mechanism. The reported mechanism for C a (outlined with the bold
line) is an ordered Bi Bi mechanism where ATP and then the phospho-acceptor
(substrate) bind C a, followed by the transfer o f the ATP y-phosphate to the
substrate, the release o f the phospho-substrate and finally release o f ADP (the
reported rate-limiting step). The phospho-acceptor can also bind before the ATP
(outlined with the thin line), but this forms a catalytically slow intermediate that
cannot contribute to the overall mechanism.
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. The measured ADP-off rate for C a was about 9-times faster than that o f Cy, a result that
is in agreement with steady-state kinetics measurements, but one that needs to be
repeated for validation. Unfortunately making this measurement required the use o f the
entire stock o f purified Cy and purification o f recombinant Cy still remains a challenge,
so at present repeating this measurement cannot be done. The result from this experiment
provides a tempting explanation to the biochemical differences observed between C a and
Cy, suggesting that C a releases its product (ADP) more rapidly than Cy during the ratelimiting step o f the reaction. Thus, since Cy cannot catalyze a reaction any faster than the
slowest step o f its catalytic mechanism and this step is nine times slower than that o f C a,
it is possible to outline a mechanism based on their rate differences for the rate-limiting
step to explain difference in their biochemical function, which is explored here.
MA TERIALS AND METHODS
Plaque Assay and Viral Stock Amplification - To determine the titer o f recombinant
baculovirus stock, Sf9 cells from a spinner flask were added to 60 mm plates
(1.5xl06/plate) and treated with 0.5 mL o f viral stock dilutions (initially 10~'-10"3) for one
hour, room temperature, with continuous rocking. After an hour the virus stock was
removed and the cells were covered with a 5 mL overlay o f 0.5% agarose in growth
media (SeaPlaque Agarose, low gelling temperature, FMC) and incubated at 27°C for
five days. The cells were then stained with viral dye overlay by covering each plate with
3.3 mL 0.06 mg/mL Neutral Red (3.3mg/mL stock, Sigma) in 0.5% agarose and
incubated at 27°C overnight (Figure 18). Plates were analyzed by counting number of
plaques/plate on a white light transilluminator and calculating plaque forming units (pfu)
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as follows: pfu/mL = (averageplaques/plate) x 2 x (viral stock dilution).
Viral stocks were amplified by adding 0.25 mL viral stock to 15 x 106 Sf9 cells in
a T162 cm flask, rocking flask for one hour at RT, adding 15 mL growth media and
incubating at 27°C for five days. Supernatant was harvested and characterized through
plaque assay to determine final titer. Optimal titer range is 106-107 pfu/mL.
Expression o f his-tagged Catalytic Subunits - The 1.2 kb Cy cDNAs (158) was cloned
separately into the Bam Rl site of baculovirus transfer vector pVL1393 (Invitrogen).
Homologous recombination to produce Cy baculovirus stocks occurred through
cotransfection o f 2 x l0 6 Sf9 cells for 4 hours at 27°C with 2 pg baculovirus DNA
(AcNPV DNA) and 3 pg o f pVL1393-Cy transfer plasmids. Recombinant Cy stocks were
amplified in Sf9 cells (Gibco) and plaque purified according to the manufacturer’s
protocols (Invitrogen). Clones were selected based on positive kinase activity and the
highest expressing recombinant C-subunit baculovirus stocks were chosen for further
studies. Isolates were further amplified, quantified through plaque assays (expressed as
pfu/mL) and then used to infect Sf9 insect cells for protein expression and purification.
For expression o f Cy in Sf9 insect cells (Gibco) cells were cultured at 27°C in
ExCell 420 media (JRH) serum free medium. Sf9 cells were grown in monolayer to 70%
confluency (approximately 15xl06 cells/T150 flask), infected with baculovirus (80
pfu/cell) and incubated for three days at 27°C. Sf9 cells that overexpress kinases, such as
C a or Cy, undergo morphological changes that are distinct from the classic rounding
morphology induced by wt baculovirus infection (159). The morphology o f infected Sf9
cells changed from small spherical cells (Figure 19A) to large round cells (1-2 days post
infection) and finally developed single or some times double extend processes, which

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

76

Fig 18. Picture of plaques following neutral red overlay. The four plates in the
picture include control (C), along with 10'5 (-5), 10'6 (-6), and 10'7 (-7) dilutions of
the his6-Cy expressing baculovirus stock.

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

77

B

A
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4 ^
19. Micrograph of morphology changes observed in Sf9 Cells after a threeday infection with Cy-gene carrying baculovirus. A, A micrograph o f uninfected
Sf9 cells which exhibit classic Sf9 cell morphology. B, A micrograph o f Sf9 cells
infected three days, expressing Cy, which indirectly causes the polymerization of
cytoskeletal proteins. This leads to the formation o f structural processes protruding
from the cells (marked by the arrows), which resemble tails and serve as markers for
Cy expression in the cell. Images were taken on an Olympus 1X70 inverted
microscope with an Olympus CCD computer-controlled camera (Olympus America,
Melville, NY).
F ig .
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resembled tails (2 to 3 days post-infection) (Figure 19B). Similar morphological changes
were observed in Sf9 cells expressing recombinant C a, however C a was not purified
from Sf9 cells as its expression in this cell line was lytic and resulted in large loss o f the
protein prior to purification step (2 0 ).
For purification of human his 6-Cy, Sf9 cells were grown to 70% confluence in
spinner flasks (approximately 2 xlO 6 cells/mL in 1L o f growth media), infected with his 6 Cy-baculovirus (80 pfu/cell) and incubated for three days at 27°C. Infected Sf9 cells were
centrifuged (1,500 x g for 5 min) and stored at -80°C as 500 xlO 6 cell/aliquots. Aliquots
were homogenized in 15 mL binding buffer (50 mM KPO 4 , pH [7.9], 250 mM KC1) with
2 mM PMSF using a ground glass dounce homogenizer (Pyrex). The homogenate was
centrifuged (15,800 x g for 30 min at 4°C) and the supernatant was applied to a 15 mL
Ni-IMAC column (=3x10 7 cells/ml resin). The column was washed with 3 CV o f binding
buffer, 10 CV o f wash buffer (binding buffer with 60 mM imidazole) and eluted with an
80 mL 60-600 mM imidazole gradient in elution buffer (binding buffer adjusted to pH
[6.4]), while collecting 1 mL fractions. Fractions were assayed for kinase activity.
Fractions exhibiting the highest specific activity were pooled and concentrated with
Amicon U ltra-15 Centrifugal Filter Devices (Millipore, 10, 000 MWCO). The protein
peak elution occurred at ~ 350 mM imidazole. The purified protein had a SA o f 0.5 U/mg
and was analyzed for purity by SDS-PAGE subjected to silver staining, coomassie
staining or Sypro Ruby Staining (Molecular Probes).
Recombinant murine hisio-Ca was expressed from a pET16b expression vector
from IPTG (0.40 mM final) induced BL21(DE3)pLysS (Novagen) transformed
competent cells grown overnight in the presence o f ampicillin (50pg/mL) at 37°C. For
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1L of transformed cells (~3g cells), cell suspension was centrifuged at 11, 500 g (JA14
rotor, Beckman J2-MI), at 4°C, for 2h. The supernatant was discarded and the cell pellet
stored at -80°C. Cells were harvested in 20 mL binding buffer (50 mM NaPCL, pH [7.9],
0.5 M NaCl, 10% glycerol) with 2 mM PMSF. The cells suspension was sonicated 5 x
6sec (mid-setting on a 550 Sonic Dismembrator, Fisher Scientific), while on ice, with 1
min between sonications. Extract was loaded onto a pre-equilibrated 7 mL Ni-IMAC
column (ProBond, Invitrogen) and washed with 10 CV wash buffer (binding buffer with
60 mM imidazole). Initially the enzyme was eluted with an 80 mL 0.06-1.0 mM
imidazole gradient in binding buffer, while collecting 1 mL fractions, with the elution
peak at about 350 mM imidazole, followed by separation on a Sephadex S300 gel
filtration column. It was subsequently found that similar results were obtained if the
protein was eluted with a 20 mL imidazole gradient off a 2 mL Ni-IMAC column, while
forgoing the gel filtration step. Both approaches provided about 5.5 U/mg o f pure hisioC a. Unphosphorylated hisio-Ca was expressed in BL21(DE3)pLysS cells in the presence
o f 100 pM

H89 (10 mM stock in DMSO) and purified through Ni-IMAC

chromatography.
Protein assay- total protein was analyzed via three different methods, Protein Assay
(BioRad), based on the Bradford reaction assay, NanoOrange (Molecular Probes), a
fluorescent protein assay, or through use o f the extinction coefficient for each o f the
proteins. All three methods provided comparable values (provide extinction coefficients
for each catalytic subunits).
Stopped-flow kinetic measurements- All transient kinetic measurements were made
similar to methods described elsewhere (155,160) using a KinTec stopped-flow
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spectrometer. Briefly, samples were mixed 1:1 in the instrument cuvet using two (single
mixing) or three (double-mixing) syringes. The excitation wavelength was 290 nm, and
fluorescence emission was measured using a 420 nm cutoff filter. The instrument
collected data points for 0 to 12000 ms time frames in each experiment (logarithmic time
base). For data analysis, the average o f three individual traces was used and the
fluorescence data were recorded as volts. Rate constants and amplitudes were obtained by
fitting o f the data to equations describing a single or double exponential growth/decay
using KinTec software. All fluorescence measurements were made in buffers containing
50 mM Mops, pH 7.0, measured at both 4°C and 25°C.
Protein Kinase Assays A nd Steady State Kinetic Determinations - In the standard kinase
32

assay, the activity o f the C-subunits was determined by the transfer o f y- 'P-ATP (200
pM) to peptide (65 pM Kemptide, LRRASLG) in the presence and absence o f the protein
kinase inhibitor peptide (amino acids 5-24) PKI 5.24 (2 pM), as previously described (20).
Steady-state kinetic constants (Km and Vmax) for purified C a and Cy were
determined using a modified protein kinase assay. Briefly, a 50 pL reaction mixture
contained 30 pL test mix (50 mM Tris-HCl (pH 7.0), 200 pM ATP, 20 mM magnesium
acetate, 10 mM DTT, and y32P-ATP (300 cpm/pmol)) and 10 pL substrate. The reactions
was initiated with the addition o f 10 pL o f the enzyme and incubated at 30 C for ten
minutes, spotted on P-81 paper and placed in 75 mM phosphoric acid to terminate the
reaction. The strips were washed in phosphoric acid 4 or 5 times, for ten minutes each
wash, washed once in ethanol, and allowed to dry before being placing in liquid
scintillant. Specific activity measurements were incubated for 2, 4, 6, 8 and 10 minutes.
Various concentrations o f the substrates kemptide (1.9-435 pM ) were used to determine
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Km and Vmax values. The determination o f apparent Km for the phosphate donor substrate
ATP was done using a non-radioactive kinase assay (Appendix H).
Immunoblots - Samples were separated on a 9% SDS-PAGE gels with a 4% stacking gel,
transferred and treated with antibodies as described previously (105). A rabbit polyclonal
antibody to C a from Santa Cruz Biotechnology (sc-903, 1:1000) that cross-reacts with
both C a and Cy was used to identify the purified recombinant proteins. Following
primary antibody treatment and washes, the membranes were incubated with HRPconjugated anti-rabbit polyclonal antibody (Amersham Biosciences) at a 1:1000 dilution
and washed. The membranes were developed using Amersham’s ECL detection kit and
imaged electronically (BioRad’s VersaDoc imaging system).
RESULTS
Purification and characterization o f his-Ca and Cy- Pure recombinant Cy had previously
been obtained using a non-conjugated protein, requiring two chromatographic steps for
purification, first with carboxymethyl (CM) ion-exchange chromatography followed by gel
filtration chromatography (20). The advent of LC-MS/MS technology (please see Chapter
III) provided one more method to characterize purified recombinant Cy. LC-MS/MS
analysis o f in-solution digest o f purified Cy (method described in Chapter III) identified
peptides to six proteins (Figure 20): (1) baculovirus p48 (YFNQSLIVDSK, Xcorr 3.97,
ACorr= 0.16; YSDENINLLIHK Xcorr 3.78, ACorr= 0.25; SSFENQANNTDNIHNVK,
Xcorr 3.32, ACorr= 0.41), (2) serum albumin precursor (LGEYGFQNALIVR, Xcorr 4.13,
ACorr= 0.31; DAFLGCFLYEYSR, Xcorr 3.28, ACorr= 0.42; HLVDEPQNLIK, Xcorr
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None of the fragments were matched the Cy sequence.
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2.99, ACorr= 0.25; KVPQVSTPTLVEVSR, Xcorr 2.83, ACorr= 0.14), (3) human keratin
type II cytoskeletal 1 (SLDLDSIIAEVK, Xcorr 2.79, ACorr= 0.17; TLLEGEESR, Xcorr
2.54,

ACorr=

0.12),

(4)

(LS AIY GGTYMLDKPIDEIVLGEGGK,

GDP
Xcorr

dissociation
5.77,

ACon=

inhibitor
0.48;

SPYLYPMYGLGELPQGFAR. Xcorr 5.43, ACorr= 0.42), (5) chain A crystal structure of
caspase-8/p35 complex (DYSDQMDGFHDSIK, Xcorr 5.77, ACorr= 0.48); and (6) E
chain, leech-derived tryptase inhibitor (IITHPNFNGNTLDNDIMLIK, Xcorr 4.30, ACorr=
0.40). None of the peptides identified corresponded to Cy, suggesting that Cy was not the
most abundant protein isolated from its purification. This became a major concern because
all of the enzyme assays performed to characterize Cy are dependent on an accurate
measure o f its concentration in the reaction, which becomes a problem when a contaminant
is present in the sample.
Another approach was devised to purify baculovirus-expressed recombinant Cy
from Sf9 cells to improve resolution during purification and to minimize the
chromatographic step required for purification. The Cy ORF was inserted into a vector that
would express it with the addition of six histidines to its amino terminus to allow for
immobilized metal affinity chromatography (IMAC) purification using N i2+- or Co2+chelated resin (Described in Materials and Methods). After comparing Ni and Co resin for
Cy purification, it was found that Cy had a higher affinity for the Ni-chelated resin (eluting
at350 mM imidazole) than for Co-chelated resin (eluting at 150 mM imidazole), making
Ni-resin favorable to minimize the loss of Cy during binding and washing steps o f the
purification. But this approach still proved difficult in part because it was difficult to
optimize Cy expression in Sf9 cells. Also, Sf9 cells contain a population o f proteins that
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bind the Ni resin (Figure 21). Because o f this, resolution o f endogenous Sf9 proteins from
baculovirus expressed Cy was also difficult (Figure 21). Fractions containing Cy had to be
selected after protein levels in the elution profile dropped, leading to a loss o f Cy in the
shoulder where overlapping occurred between Cy and Sf9 cell-protein (Figure 21). Once
expression and purification conditions were optimized Cy was expressed and purified from
Sf9 cells with yields o f 2mg of recombinant protein that were >80% pure (Figure 22).
Fligh-yield, homogeneous purification o f C a ectopically expressed in bacteria is relatively
straightforward and well documented (96,139,161). Hisio-Ca was purified here so that both
isoforms could be compared containing the same type o f modification.
Recombinant his6-Cy and hisio-Ca were characterized through steady-state kinetics
following purification using Kemptide as a substrate, and were analyzed with EaddieHofstee plots (Figure 23). Results from this characterization suggest that Cy’s affinity for
Kemptide is about 5 times higher than previously reported with the non-his tagged isozyme
(Km= 4 + 2 pM, average ± standard error, n= 9), while hisio-Ca exhibited similar affinity
for Kemptide as measured with the non-his tagged isozyme (Km= 23 + 10 pM, average ±
standard error, n= 7). These averages represent measurements made from several different
preparations over the past five years. An average for their Vmax could not be made, as many
o f the preparations made were not pure enough for an accurate determination o f Cy protein
concentration in the preparation.
Stopped-flow characterization o f Ca-ATP binding ra tes- The ATP binding rates were
determined with C a, but not Cy, because o f the high amounts o f C a readily obtained
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F ig . 21. Cy nickel IMAC purification profile. This profile represents the best
resolution obtained between cellular lysate proteins (closed circles) and Cy
activity (open circles). In this experiment fractions 45-57 were pooled together
for the concentration step to avoid inclusion of contaminant proteins.
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F i g . 22. SDS-PAGE analysis of C-subunit purification. Purification o f
both C-subunits was followed by silver stain gel analysis. A, purification
profile for his6-Cy, which corresponds to the purification profile in Figure 20.
Lane 1, molecular weight marker; 2, empty; 3, extract; 4, flow through; 5,
wash 1; 6, wash 2; 7, elution o f fractions 37-44; 8, elution o f fractions 45-57;
9, empty; 10 pooled and concentrated fractions 45-57. B, gel showing
purified hisio-Ca.
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through expression and purification from bacteria and the low expression levels o f Cy in
Sf9 cells. Stopped-flow characterization o f C a has been done using several approaches
(38,155). The approach used here employs fluorescence resonance energy transfer (FRET)
to measure the binding and release o f ATP from C a ’s active site (155). The principal of
this approach is that exciting tryptophans in the C a active site at 290 nm, releases energy
(320-340 nm) exciting mantATP as it comes into proximity with the C a active site, reemitting energy at >420 nm as it does so, which is measured by the stopped-flow
fluorometer. Thus, as mantATP binds the C a active site an increase in fluorescence is
measured, recorded as volts, and plotted. The binding rate (or rates) is determined by the
equation used to fit the hyperbolic curve measured.
Two rates were measured for Ca-mant-ATP binding at 25°C. The first rate (ki) is a
very rapid increase in fluorescent signal followed by the second rate (k2 ), which is a slower
decrease in signal (Figure 24). Rates ki and k 2 were measured at several concentrations of
mantATP and plotted (Figure 25). The slope for the first rate, ki, was found to be mantATP
concentration-dependent (1.6 x 106 M/sec). The slope for k 2 did not change with changing
concentrations o f mant-ATP (19 s"1). The slope of the k l linear-curve corresponds to C a ’s
binding rate for mant-ATP, which is within experimental error of the value reported in the
literature. As reported, this rate is very rapid, but not as rapid as diffusion-limited reaction
rate (108), where the reaction occurs as rapidly as the molecules can encounter.
The mant-ATP binding was also measured at 4°C. At this temperature several
interesting things were observed. First was that the mant-ATP binding rate is similar at
both temperatures (ki(4°Q= 1.9 x 106 NT’sec"1). The second observation is that three rates
were measured at 4°C (k2(4 °c)= 0.3sec_1, k 3(4 »C)= O.Of^sec'1). The second and third rates at
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4°C are mant-ATP concentration independent. The second rate measures an increase in
fluorescent signal (amplitude2oo pm mant-ATP= -0.0662) and the third rate measures a decrease
in fluorescent signal (amplitude 2oo pMmant-ATP= 0.0165).
The mant-ATP binding was also measured at 25°C in the presence o f Kemptide to
determine whether the presence o f the phospho-acceptor substrate affected the observed
binding rate o f the nucleotide substrate (Appendix J). This was done by mixing 13 pM C a
from one syringe with 100 pM mant-ATP and varying concentrations o f Kemptide (25-400
pM) in the other syringe. The slopes for the two rates measured at 25°C, ki and k 2 ,
decreased very slightly with increasing amounts o f Kemptide (kj Kemptide: y = -0.1961x +
296.43, R2 = 0.3865; k 2 Kemptide: y = -0.0063x + 11.038, R2 = 0.0278), but it is not clear if
these slopes fall within the error measured for each rate. A similar trend is observed in the
amplitudes for each rate (amplitude]KemPtide: y = -O.OOOlx - 0.1012, R2 = 0.5346;
amplitude2Kemptide: y = -7 x 10'6x + 0.0123, R2 = 0.085). The correlation values for these
curve fits are not very good, suggesting that there is little difference between the measured
rates or amplitudes at each Kemptide concentration. However, there is a decrease in the
amplitude of k2 relative to the amplitude measured in the absence o f Kemptide, suggesting
that Kemptide affects the step corresponding to k 2 . The ATP-off rate for C a was
determined through two independent approaches. The first was simply the y-intercept of
Figure 25, the slowest rate of the mantATP binding rate curve, 174sec"'. The second
approach was through double-mixing stopped-flow (Figure 26) In this approach mant-ATP
was first mixed with C a, followed by a second mix with a high concentration o f ATP (3
mM). The ATP binds the C a active site, displacing mant-ATP as mant-ATP dissociates
from the active site.

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

90

2.45

2.4

2.35

0.0

0.012

0.12

1.2

12.0

TIME (sec)
F ig 24. Binding of mant-ATP to C a measured using stopped-flow
spectroscopy. Time-dependent change (x-axis) in fluorescence in volts (y-axis)
upon mixing 4 pM C a and 400 pM mant-ATP at 25°C. Two fluorescent signals
are observed, ki, which increases with time and k 2 , which decreases with time.
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25. Effects of total mant-ATP concentration (12.5-200 pM) at
25°C. The plot shows rates k l and k2 measured against several
concentrations o f mant-ATP (x-axis). A rate was measured for 400 pM
mant-ATP, but this rate fell off the linear curve and did not fit a
hyperbolic curve with statistical confidence.
F ig .
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This rate is independent o f ATP concentration and is measured as a decrease in
fluorescence, which corresponds to the mant-ATP off-rate (174sec_1). As can be seen the
value from this measure is in excellent agreement with the value obtained from the yintercept in Figure 25 (173.65sec_1) and this value is in good agreement with the value
reported in the literature (lOOsec-1)! 155).
Stopped-flow characterization o f C a and Cy ADP dissociation rates- Once satisfactory
measures were made with mant-ATP and C a, it was o f interest to measure the mant-ADP
off-rates for C a and Cy. The release of ADP is reported to be the slowest step in C a ’s
mechanism (Figure 15), thus it is described as its rate-limiting step. This measure was done
here through double-mixing experiments where the isoforms were pre-mixed with mantADP, followed by the addition of high concentrations o f ATP (3mM). The Ca/mant-ADPoff rate (35sec'*) was determined from a fit o f the curve measured as the fluorescent signal
decreases while the mant-ADP is trapped off the catalytic subunit (Figure 26A), and is in
agreement with the literature (75sec_l) (38,155). A very low signal was obtained when the
same experiment was done with Cy (Figure 26B), but a reproducible rate was measured
(4.1 ± 0.3 sec'1; Avg. + Std. Error, n = 3). The rate measured for the Cy mant-ADP off-rate
is nine times slower than the C a rate. Unfortunately, this approach used the entire stock of
purified Cy, and complications o f Cy expression prevented repeating the experiment.
DISCUSSION
Biochemically, C a and Cy differ in their steady-state kinetics for classic PKA substrates,
including histone and Kemptide (20), specifically the Cy Vmax is ten-times lower than that
o f Ca. One possible explanation for this difference is that Cy has slower substrate binding
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26. Double-mixing experiment trapping mant-ATP
from C a at 20°C. 8 pM C a was pre-mixed with 200 pM mant
ATP in one syringe, and then rapidly mixed with 3 mM MgATP. The data was fit with a double-exponent function to
obtain the rates k l= 174 s '1 and k2= 3.8 s '1.
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27. Double-mixing experiment trapping mant-ADP from C a and
Cy using ATP at 20°C. A, 12 pM C a was pre-mixed with 200 pM mantADP in one syringe and then rapidly mixed with 3 mM Mg-ATP. The data
was fit with a double-exponent function to obtain the rate for k l= 34.5 s'1
(amplitude= 0.277). B, 6 pM Cy was pre-mixed with 100 pM mant-ADP in
one syringe and then rapidly mixed with 3 mM Mg-ATP. The data was fit
with a double-exponent function. The first component was ignored here as it
reflects an increase in mant-ADP. The rate for k2= 4.0 s-1 (amplitude=
0.00749) is the rate for the dissociation o f mant-ADP from Cy.
F ig .
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and/or release rates, slowing down the rate o f its catalytic mechanism. If true, this would
explain why Cy exhibits lower CREB-mediated reporter activity, as this mechanism
depends on the C-subunit phosphorylating CREB at S I33 (162). Thus Cy would
phosphorylate 0.1 of the CREB molecules that C a would, causing a ten-fold difference in
reporter-activity measured, which is what is observed in some cell types (105). Here we
studied the catalytic mechanisms o f both C a and Cy through stopped-flow analysis using
fluorescent-labeled ATP and ADP substrates, which are the first substrates to bind and last
product to leave the C-subunit catalytic active site (34,155).
Two general classifications serve to describe the kinase kinetic mechanism based
on the data from steady and pre-steady-state kinetic studies and crystal structure analysis of
more than thirty kinases (163). Mono-substrate kinetics is a relatively simple model used to
teach enzyme kinetics and is easily described by the Michaelis-Menten equation (164).
However kinases catalyze the reaction between two substrates (a nucleotide triphosphate
and a phosphoacceptor), making the reaction more complex. However, when the
concentration for one substrate is held constant the Michaelis-Menten equation still holds
true for the second substrate (165), providing an approach to study the two-substrate
mechanism of an enzyme. The steady-state kinetic characterization is determined once all
of the reaction components (enzyme, co-enzymes and substrates) have reached equilibrium.
This provides a lot o f information but is limited because this type o f characterization is not
able to easily differentiate the binding and dissociation rates for individual ligands.
Discerning binding rates for each ligand in an enzymatic reaction helps to develop a model
for the enzyme’s reaction mechanism. A technique often used to measure the catalytic rates
is stopped-flow, which measures the rates for each ligand, when possible, before

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

96

equilibrium between enzyme and substrates is established (166). Thus, this technique
measures an enzyme’s pre-steady state kinetics.
One mechanism used by kinases is the Bi-Bi mechanism (Figure 15) where the
order in which the NTP and the phospho-acceptor substrates bind the enzyme may
(ordered Bi Bi) or may not (random Bi Bi) matter. The key to this mechanism is that no
phospho-enzyme intermediate is formed instead the enzyme directly transfers the NTP
phosphoryl group to the phospho-acceptor substrate. Hexokinase is an example o f an
enzyme that follows this mechanism; serine-threonine kinases also follow this
mechanism (157,163,167). The second mechanism for kinases is the Ping Pong Bi Bi
mechanism wherein the kinase binds an NTP and catalyzes the transfer o f the NTP
phosphoryl group to its own active site. The remaining NDP is then released from the
kinase, leaving behind a phospho-kinase enzyme intermediate, which then binds the final
phospho-acceptor substrate, catalyzing the transfer o f the phosphoryl group to the
substrate.

Examples

of this

mechanism

include

alkaline phosphatase,

tyrosine

phosphotransferases, nucleotide diphosphate kinase, and P-ATPase (168). A point of
controversy concerning protein kinase that utilize the ordered Bi Bi mechanism is
whether the phosphoryl transfer occurs through an associative

(S n2 )

mechanism, where

there is no phosphoryl intermediate formed between the enzyme and substrates within the
active site o f the enzyme or a dissociative

(S n I)

mechanism where a phosphoryl

intermediate forms prior to phosphoryl transfer (26,169,170).
The mechanism described for C a is an ordered Bi Bi mechanism (Figure 15)
(34,171,172), where the literature favors the in-line associative transfer o f the phosphate,
and the release o f ADP as the rate-limiting step (34,35,155). The results presented here,
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while far from being conclusive, seem to support the published mechanism for C a, where
the ATP binding rate is very rapid (Figure 24) and the ADP release is much slower
(Figures 26). However, the results presented here and published elsewhere (155) make it
clear that the C a catalytic mechanism is not as straightforward as depicted in Figure 15
(171,172). Stopped-flow analysis o f the ligand binding rates for ATP and ADP were
studied here through use o f fluorophore conjugates nucleotides, mantATP and mantADP, which serve as good analogues to study ATP and ADP binding to C a (155).
Stopped-flow analysis presented here o f mant-ATP binding C a at 25°C measures two
rates, ki which is a rapid increase, mant-ATP concentration-dependent rate, and k 2 which
is a slow decrease, mant-ATP concentration-independent rate. This suggests that there are
at least two steps involved in the binding o f mant-ATP. Ni et al. measure three rates for
this step (155), the first two match the ones measured here, and the third one is also
ligand concentration-independent but slower than k 2 , suggesting that there may be a third
step to C a binding mant-ATP. Results presented here o f mant-ATP binding C a at 4°C
measure three rates, but unlike the published work at 25°C the second rate also measures
a slow increase in fluorescent signal, thus at 4°C there are two rates that measure an
increase in signal and a third that measures a decrease in signal. The third rate measured
at 4°C would coincide with k 2 measured at 25°C, but it is much slower than would be
predicted by estimating a two-fold decrease every 10°C, suggesting that this rate is very
temperature dependent, which may mean it is measuring a conformational change in C a.
Between the work presented here at 4°C and 25°C and the published work there are four
measured rates, suggesting that there may be three steps in the binding o f mant-ATP. The
mant-ATP off-rate for C a was arrived at via to independent approaches, which were in
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very good agreement with each other (174 sec'1) and in good agreement with the
published work (165 sec'1 and 190 sec'1) (155).
The C a mant-ATP on-rate was also measured in the presence o f Kemptide, which
is a second substrate for C a, to determine if having both substrates present affected either
of the mant-ATP rates measured at 25°C. A common trend was observed in this
experiment for both rates measured and their corresponding amplitudes, and that was that
there seemed to be a decrease in both rates and amplitude as the Kemptide concentrations
increased. This would suggest that high concentrations of the phosphoacceptor would
slow down the ATP binding-rate. One interpretation o f this may be that at higher
phosphoacceptor concentrations two enzyme species are formed, one wherein the ATP
bound before the phosphoacceptor and a second where the phosphoacceptor bound the
kinase before ATP. It is not clear without further experiments whether the later species
described would undergo FRET, but if the phosphoacceptor were to bind the kinase first
this may lead to a change in the amplitude o f second signal. However the correlation
values for these experiments are very low suggesting that either there were outliers in the
experiment or that there really is no trend and having Kemptide present does not affect
the ATP binding rate. At this point the experiment has not been repeated enough times to
statistically discern between these two possibilities.
The ADP off-rate for both C a and Cy was measured through double mixing
experiments, in which the kinase was first mixed with mantADP and then mixed with
ATP. The results presented here agree with the release o f ADP as the being slower than
ATP on or off-rates, and thus would fit as the rate-limiting step for C a. The C a mantADP off-rate was approximately five-times slower than the ATP off-rate and ten-times
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slower than the measured ATP-on rate. These rates are also in good agreement with the
reported mechanism for C a, where ATP binds first, followed by binding of the
phosphoacceptor,

the phophorylation o f this

substrate and the release o f the

phosphorylated substrate, leaving ADP in the active site, which is released last (Figure
15). Furthermore, the results presented here for C a are in good agreement with the values
reported in the literature (155). Flowever, this mechanism (outlined in Equation 2) does
not take into account the second rate (k 2 ) measured for mant-ATP binding C a, which was
measured here as being slower than the mant-ADP off-rate (k7), but was reported
elsewhere not to be statistically different from the mant-ADP off-rate (155). This raises
the question, is mant-ADP dissociation truly the rate-limiting step for this reaction? The
discrepancy rests with which experimental values are accepted to be true.
One approached used here to try and answer this question was to determine the
turn-over rate or kcat for the purified C a used in these experiments and compare it to the
different rates measured here. While the significance o f kcat to a mechanism depends on
the nature o f the mechanism it should coincide with the rate-limiting step o f the reaction.
Upon calculating the turn-over rate for the pure C a used in these experiments it was
found to be about ten-times slower (3.9 sec'1) than the slowest rate measured or any
published turn-over rates which range from 52 sec'1to 20 sec'1(37,87,156). This suggests
that there was about five-to-ten-times less active C a in the prep used here as the
calculation depends on the total concentration o f enzyme used (kcat= Vmax/[Etot]). This
observation may explain why a third rate (k 3) was not measured at 25°C, as here we may
have had less available enzyme in the reaction as in the published work (155). A decrease
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in the amount o f enzyme would cause a decrease in the amplitude o f the signal measured,
making it more difficult to fit the curve to the low signal o f a slow rate.
Based on the work presented here and published elsewhere there are at least seven
different steps to the C a catalytic mechanism. A mechanism is displayed in Equation 2
that attempts to consolidate all o f the rates measured or published for C a, where ki (1.6 x
106 M '1 s '1), k_i (174 s '1), K2 (19 s '1) and k7 (35 s'1) were determined here. Rate k 3 is
based on published work (155). Rate k 4 , while not measured will depend on the catalytic
k,
k2
k3
k4
^5
C + ATP <-> C*ATP <-> C*ATP’
C*ATP + S o C*ATP*S <->
k-2
k_3
k.j
k-4
k-5
k6
C*ADP*P

(2)

k7
C*ADP + P <-> C + ADP

k_6

k_7

subunit (C) affinity for the phosphor-acceptor (S), k5 is the rate o f the chemical phosphortransfer and k6 will depend on the dissociation rate of the phosphorylation product (P). It
is not clear from the experiments done here if the C a Km for Kemptide (23 pM) is
equivalent to kfi in Equation 2.
This is the first time pre-steady state kinetics have been measured with Cy. The
challenge for this experiment was in isolating sufficient protein to make the
measurements. Here sufficient Cy was isolated to measure its binding rate with one
nucleotide. As the release of ADP is the rate-limiting step for C a, it was felt that this was
a likely step where C a and Cy mechanisms might diverge and thus chose to use what
sample was available from purifying Cy to study its ADP off-rate. The signal measured
for this step was very weak and did not provide a curve that was very distinct from the
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mantADP background signal. However, the signal obtained from double mixing
mantADP and ATP to measure the off-rate provided a reproducible exponential curve fit
for Cy with a slope nine-times slower than that o f C a. Because the signal was so low it is
not clear if the slope measured is accurate or if the weak signal is due to insufficient
quantities o f functional protein. The latter is a likely possibility because pure recombinant
Cy is not very stable at -80°C or in N 2 (/), so it is possible that only a portion o f the
protein in the purification preparation was functional, which would yield a lower signal in
the stopped-flow experiments. However, the concentrations o f enzyme used for C a and
Cy were calculated to be the same in these experiments and the steady-state kinetic
measures with this Cy prep allowed for the highest dilution o f Cy made to date, lOOx,
suggesting that there was more enzyme than usual obtained from this purification, but
this does not mean that there was enough active Cy for this type o f experiment. Once
sufficient Cy can be purified to repeat these experiments the enzyme should be tested in
binding assays with pure recombinant R-subunits, an approach that will stochiometrically
identify the concentration o f active Cy in the preparation, as only functional Cy will bind
the R-subunit (173). This measure will provide a starting point for an accurate measure of
each isoforms tested in the stopped-flow experiments.
If the values measured here for C a and Cy are accepted as accurate, then the
difference in rates for the release o f ADP can be used to outline an equation that could
explain why Cy is kinetically slower than C a (Equation 3), wherein if the equilibrium
rate between the different species o f C-ADP (K) or the dissociation rate o f C and ADP (kADP) is very different between the two catalytic subunits the equation could explain
differences observed (Appendix E).
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Differences in reaction rates may be due to overall differences in their tertiary
structure, as illustrated by Cy having a smaller stoke’s radii (20) (Appendix F), suggesting
an overall different shape than C a. This may affect interactions in the active site making
Cy less efficient at phosphorylating, as demonstrated by Vmax:Kmratios for Kemptide and
K
k-ADP
C*-ADP <==> C-ADP —> C + ADP

n)

Histone (20). The difference in Stoke’s radius between the two catalytic subunits may also
reflect that purified recombinant his-Cy is improperly folded. But this is unlikely because
the measurement of the radius is dependent on determining where the protein elutes off
size-exclusion chromatography and this is determined by kinase activity. This is, the
measured radius is based on an active enzyme, which should be folded sufficiently to be
active. It is also possible that his-Cy is miss-folded, still active, but not as active as
endogenous Cy. But this is difficult to confirm as endogenously expressed Cy has yet to be
isolated from any tissue and characterized.
There are several key residues that are important to the inline-transfer between ATP
and the phosphoacceptor, including K72, the G-triad, G50, G52 and G55, D166, K168,
N171 and D184 (118,157,174). All o f these are conserved between C a and Cy and depend
on the distances within the active site for proper proximity to the substrates. It is possible
that these distances are disrupted in Cy, affecting the interaction between the residues and
the substrates, and this effect is manifested as a slower catalytic rate for Cy. This model
would be difficult to test through point-mutants as it depends on determining the position of
each residue within Cy’s active site. The best way to test this is through determining the
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crystal structure of Cy, an approach that requires high quantities o f highly pure protein,
something that remains elusive in the characterization o f Cy.
The results presented here however support the hypothesis that differences in
kinetics between C a and Cy are in part due to differences in the rates o f their rate-liming
step as the differences observed in this rate-limiting step agree with differences observed in
steady-state kinetics and transient reporter assays. The physiological ramifications o f the
biochemical difference between C a and Cy still needs to be determined through studies of
the isoforms in vivo and in the intact cell.
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C H A PTE R V

D IFFER EN T IA L EX PRESSIO N O F cA M P-DEPENDENT PR O T E IN KINASE
C a AND Cy ISO FO RM S IN U-937 C ELLS

ABSTRACT
The cAMP-dependent protein kinase (PKA) catalytic subunits Cy and C a share
83% identity in primary structure but differ in chromosomal location, gene structure,
gene transcription regulation, kinetics, and specificity for peptide substrates and
pseudosubstrates. In contrast to the ubiquitous expression of C a, Cy is primate-specific
and mRNA has been identified only in human testes. For the first time we present the
selective identification o f endogenous Cy protein and mRNA expressed in human U-937
cells. Increases in protein kinase inhibitor (PKI)-insensitive, cAMP-dependent kinase
activity following 8-CPT-cAMP-induced differentiation o f U-937 cells suggested an
increase in Cy expression during differentiation, while total PKA catalytic activity did not
change. A new antibody identified a 40-kDa band following differentiation o f U-937
cells and RT-PCR/RFLP analysis demonstrated that Cy mRNA was present before and
after differentiation. DEAE chromatographic analysis o f U-937 cells showed that the
PKA profile changed from similar levels o f type I and type II PKA in undifferentiated
cells to 100% type I in differentiated U-937 cells. Furthermore, 60% o f PKI-insensitive,
cAMP-dependent activity in U-937 cells was associated with type I PKA suggesting Cy
favors association with type I PKA in this cell line. These results expand our
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understanding o f structure-function roles for PKA isoforms in cell differentiation and
function. Furthermore the increase in Cy expression during U-937 differentiation suggests
a novel function for Cy in the cell.
INTRODUCTION
The cyclic AMP-dependent protein kinase (PKA, EC 2.7.1.37) is a member o f the
AGC serine/threonine kinase family (2), which phosphorylates hundreds o f substrates
involved in numerous physiological processes, such as energy metabolism, cell division,
proliferation, apoptosis, and differentiation (1). PKA is present at varying concentrations
in all tissue types (42,43) and exists as an inactive holoenzyme consisting o f a regulatory
subunit (R) dimer and two catalytic subunit (C) monomers in the absence o f cAMP. Two
types of PKA exist in the cell, type I and type II, determined by the R subunit isoform
present in the holoenzyme. There are four known Homo sapiens genes for the R subunit:
R Ia, Rip, R lla, and RIIp. Classically, PKA type I elutes from a DEAE column at lower
NaCl concentrations than type II (175). There are three genes for the C-subunit expressed
in Homo sapiens: C a, CP, and Cy (45). Human C a and CP share the highest degree of
homology in their primary amino acid sequence (93% identity) and have multiple splice
variants (49-52). C a and Cy are highly homologous exhibiting 83% identity while Cp
and Cy exhibit 79% identity (45).

Unlike the C a and Cp gene, the Cy gene is an

intronless retroposon gene, which appeared in the human genome an estimated forty
million years ago (73). Thus, Cy is the only known example o f a primate specific PKA
gene.
Ca

and

Cy differ in

gene transcription

regulation

and

substrate

and

pseudosubstrate specificities. Differences in gene transcription regulation were observed
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through transient transfections and luciferase-reporter assays where C a induced
transcriptional activation through CREB and Cy did not (105). Differences in
pseudosubstrate and substrate recognition have been observed where C a is inhibited by
protein kinase inhibitor (PKI) while Cy is not (13,20) and Cy exhibits a lower V m a x than
C a for most substrates tested (20). These differences between C a and Cy suggest that
while both enzymes are cAMP-dependent, they may fulfill different functions within the
cell.
The Cy mRNA has been identified only in human testes where it was cloned from
a human testes cDNA library (45). PKA Cs, or Ca2, has recently been identified as a
testes specific isoform, a splice variant o f C a expressed in mature sperm (52,107), but
this isoform is not human specific. Identification o f Cy in other tissues has been difficult
because o f the high homology between Cy and C a and the absence o f isozyme-specific
antibodies. Since Cy was identified in testes, a tissue with a high concentration o f cells
undergoing differentiation, it is possible that Cy has a function in cellular differentiation.
Furthermore, sperm undergo differentiation that involves specific isoforms o f the PKA
catalytic subunits (52). In addition, Cy is an intronless (73) gene, and many intronless
genes play a role in cellular differentiation (110-116). U-937 myeloid leukemia cells
were selected as a model system to investigate this possibility. This cell line can be
induced to differentiate when treated with several cAMP-elevating reagents including
forskolin and dibutyryl cAMP.
We present evidence for the first time that Cy is expressed in U-937 cells using
DEAE-Sepharose chromatography separation, kinase assays in the presence and absence
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o f PKI, immunoblot analysis with C-subunit isozyme-selective antibodies, and RT-PCR
coupled with restriction fragment length polymorphism (RFLP) analysis. Three days after
8-CPT-cAMP induced differentiation, analysis o f mRNA, protein, and catalytic activity
indicated increases o f Cy expression. These observations suggest a previously undefined
function for Cy in cellular differentiation and pose new questions concerning regulation
o f human cell differentiation by PKA catalytic and regulatory isozymes.
MA TER1ALS AND METHODS
Tissue Culture Conditions - U-937 myeloid leukemia cells were maintained in RPMI
5

1640 with 10% FBS and L-glutamine at a density o f 5 x 10 cells/mL, incubated at 37°C
and 5% C 0 2. For chromatography analysis, kinase assays, immunoblot analysis, and
6

RFLP analysis, 2.4 x 10

cells/mL in 85 mL o f growth media were induced to

differentiate with 50 pM 8-(4-chlorophenylthio) adenosine- 3', 5'- cyclic monophosphate
(8-CPT-cAMP, 10 mM stock in FLO) for three days.
6

Cell Harvest - Following a three-day treatment with 8-CPT-cAMP, 204 x 10 U-937
cells were washed with one volume o f isotonic KP buffer (10 mM potassium phosphate,
1 mM EDTA, 250 mM sucrose, pH [6.9]), sedimented (200 x g, 15 minutes), the
supernatant discarded, and the cell pellet stored at -80°C until used for chromatography
analysis.

When appropriate, cells were thawed on ice, homogenized with a Dounce

homogenizer in 2 mL KP buffer without sucrose (low ionic strength KP) containing
protease

inhibitors

(10

pg/mL

leupeptin,

20

pg/mL

pepstatin

A,

2

mM

phenylmethylsulfonyl fluoride, 2 pg/mL trypsin inhibitor and 2 pg/mL aprotonin), 10
mM 1,4-dithiothreitol, and 50 mM potassium fluoride (a phosphatase inhibitor). Cell lysis
was assessed microscopically using trypan blue. The homogenate was sedimented
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(15,800 x g, 10 minutes, 4°C), the supernatant removed and kept on ice. One aliquot of
supernatant was combined with Laemmli sample buffer (1:3, sample buffer: sample),
incubated at >90°C for 10 minutes and stored at -20°C. The remainder o f the cell extract
was used for kinase assays and chromatographic separation.
Proliferation Assay -

Proliferation rate decreases as cells differentiate. To use

proliferation as a differentiation marker, 3000-5000 U-937 cells/well in a 96 well plate
were treated with 50 pM 8-CPT-cAMP for three days and compared to untreated
(undifferentiated) cells. Following treatment, cells were incubated 30 minutes with 3(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxy-phenyl)-2-(4-sulfophenyl)-2Htetrazolium (MTS, Cell Titer 96 Aqueous One Solution Cell Proliferation Assay,
Promega), according to the manufacture’s instruction. The optical density was measured
at 492 nm for each well in a Tecan plate reader, where an increase in absorbance
corresponds to an increase in cell viability. Data are presented as the mean ± standard
error (n=5), with significance shown relative to undifferentiated, as determined by a
Student’s t-test.
Nitrobluetetrazolium Assay - Nitrobluetetrazolium (NBT) reduction by U-937 cells was
used to determine respiratory burst activity in cells differentiating toward monocyte-like
cells. The respiratory burst was also used as a differentiation marker because it includes
wide range o f sophisticated functions that are acquired during differentiation and absent
in undifferentiated cells. NBT reduction was measured in undifferentiated cells and cells
treated for 3 days with 50 pM 8-CPT-cAMP. Following three days ± treatment, lxlO 6
cells were incubated at 37°C for 45 minutes with 0.1% NBT and phorbol 12-myristate
13-acetate (20ng/mL final), applied to a glass slide (Cytospin III centrifuge, Shandon
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Southern; Sewickley, PA), stained with 0.5% safranin, and analyzed microscopically
under oil immersion. A minimum o f 200 cells/slide was counted. Data are presented as
the mean ± standard error (n=5), with significance shown relative to undifferentiated
cells, as determined through a Student’s t-test.
DEAE Chromatography Analysis o f Cell Extracts - Chromatographic separations were

performed at 4°C by loading 1.8 mL o f cell extract (an average o f 7.5 mg/ml protein in
undifferentiated cells and 0.9 mg/mL in differentiated cells as determined by BioRad’s
Protein Assay) onto a 4 mL diethylaminoethyl (DEAE)-Sepharose fast-flow resin
(Pharmacia Biotech) column, that had been pre-equilibrated with 10 column volumes of
low ionic strength KP buffer. The flow-through was passed over the column three times.
The extract was eluted with a 50 mL, 0-500 mM NaCl gradient in KP buffer, while
collecting 1 mL fractions, which were analyzed for kinase activity.
Kinase Assay -

Enzyme activity was measured in crude cell extract and from

32
chromatography samples by measurement o f P -y-ATP incorporation into Kemptide
(Leu-Arg-Arg-Ala-Ser-Leu-Glu, Bachem Bioscience Inc.) as described previously (24).
All reactions contained 78 pM Kemptide, ± 10 pM cAMP, ± 1 pM protein kinase
inhibitor (PKI). Activity was corrected for the total protein in the cell extract and
expressed as pm ol o f ATP incorporated/minute/mg total protein in cell extract.
Immunoblot analysis - Samples were separated on a 9% SDS-PAGE gels with a 4%

stacking gel, transferred and treated with antibodies as described previously (105). Three
different antibodies were used at the indicated dilutions: a rabbit polyclonal antibody to
Cy from Santa Cruz Biotechnology (sc-905, lot# A297, 1:1000), a polyclonal antibody to
Cy from Abgent (cat# AP7014a, lot# SH020924K, 1:500), and a Ca-selective monoclonal
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antibody (Transduction Laboratories, cat# P73420, lot# 6, 1:1000). Following primary
antibody treatment and washes, the membranes were incubated with HRP-conjugated
anti-mouse or anti-rabbit polyclonal antibodies (Amersham Biosciences) at a 1:1000
dilution and washed. The membranes were developed using Amersham’s ECL detection
kit and imaged electronically (BioRad’s VersaDoc imaging system).
U-937 RNA isolation and RT-PCR/ Restriction Fragment Length Polymorphism (RFLP)
analysis - This work was done by Dr. Rana C. Morris. Because o f the high homology

between C a and Cy, including the C ’ un-translated region, it was not possible to
specifically amplify either o f the isoform mRNAs without inclusion o f the other.
However, we were able to differentiate the two based on differences in restriction enzyme
sites in amplified sequences that included both C a and Cy. Untreated and treated U-937
6

cells were isolated on days 0, 1, 2 and 3. Cell pellets (2x10 cells) were lysed with Trizol
reagent (Gibco BRL/Invitrogen) and total cellular RNA (RNA ^ was isolated via
phenol/chloroform extraction followed by isopropanol precipitation, washed twice with
70% ethanol and dissolved in DEPC-treated dH20 . Purity and quantity o f both types of
RNA samples was assessed via UV spectrophotometer at 260 and 280 nm. The A26(/A280
ratios for all RNA isolates were consistently between 1.86 and 1.96.
Reverse transcription was done following manufactures instructions (AMV
reverse transcriptase, Promega). Five micrograms o f RNAfot was subjected to first-strand
synthesis by 30 units of AMV-RT with an 2.5 pg oligo (dT) primer in a total volume of
25 pL at 48°C for 60 minutes.
PCR primers were generated using sequences from the human cAMP-dependent
protein kinase catalytic subunits (Ca: NM_002730 and Cy: NM_002732) to amplify a
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portion o f PKA-Ca and -Cy based on a highly conserved region between C a and -Cy, that
significantly diverges from human Cp (NM_002731, NM_207578, NM _182948). The
primer set amplifies a 370 base pair region o f both C a (284-654nt) and Cy (256-626nt)
transcripts (forward primer: 5’-CCACTACGCCATGAAGATCCTC-3’ and reverse
primer: 5 ’-CGCGCTTGGCGAAACCGAAGTC-3 ’).
Five microliters o f the RT reaction was added to a standard PCR reaction mixture
containing 5 units Taq polymerase (Promega) and 2.5 pg o f each the forward and reverse
Ca/Cy-specific primers in a total volume o f 25 pL.

Negative controls were run to

determine if any genomic and reagent contamination was present along with positive
controls, generated by “doping” additional PCR reaction tubes with 1pg o f plasmid-based
expression vectors for C a and Cy transcripts. A 10-minute 94°C hot start began the 45cycle reaction (30 second 94°C dissociation step, 45 second 58°C annealing step and 90
second 74°C extension step) with a final 10-minute 74°C extension step added after the
th

45 cycle. PCR products were analyzed by separating 5 pL o f each reaction mixture in a
2% Tris-acetate-EDTA agarose gel before performing the restriction digestion analysis.
Five microliters of the PCR reaction were added to subsequent restriction
digestions containing 1 unit o f Rsal, PstI or Xhol (Promega) in appropriate reaction
buffers and incubated for 1 to 2 hours at 37°C. Standard glycerol-based DNA sample
buffer was added to the entire restriction digestion mixture. The samples were applied to
15% polyacrylamide gels with a 3% stacking gel and separated (30 mA, 4 hours) using a
Tris-borate-EDTA buffering system. The gels were then rocked at room temperature for
5 minutes in 200 mL ethidium bromide solution (0.25pg/mL), and imaged using a UV
transilluminator and a digital camera.
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RESULTS
Differentiation o f U-93 7 Cells with 8-CPT-cAMP - The human U-937 myeloid leukemia
cell line differentiates in response to increases in intracellular levels o f cAMP induced
with forskolin (176), but not with agonist to G-protein coupled receptors such as
histamine and dimaprit (176,177). Alternatively, the cells can be treated directly with
membrane permeable cAMP analogues such as dibutyryl cAMP (dbcAMP) (178,179) to
bypass adenylyl cyclase. However, dbcAMP breaks down into butyrate (180,181), which
can also induce differentiation o f U-937 cells (180). Another analogue that may be more
suitable for a cAMP-specific effect is 8-(4-chlorophenylthio) adenosine- 3', 5'- cyclic
monophosphate (8-CPT-cAMP). To the best o f our knowledge there are no published
reports showing U-937 cells differentiate in response to 8-CPT-cAMP. This analogue has
no known biologically active byproducts, has a higher affinity for PKA (182,183) and is
less susceptible to phosphodiesterase (PDE) hydrolysis than dbcAMP (10,184).

Dose

response studies demonstrated that the 8-CPT-cAMP EC5Q was 50 pM for differentiation
o f U-937 cells (data not shown).
Markers for U-937 cellular differentiation include a decrease in cellular proliferation and
DNA synthesis, increase in cell adherence and its associated extracellular markers CD 11
and CD 18, increase in phagocytosis and its associated extracellular marker FcyRII,
increase in respiratory burst activity, superoxide production, and their associated marker
CD14 (176,178,179,185-188). For this study we selected two o f these markers, which
include diverse cell functions and have been well established for U-937 cellular
differentiation: cellular proliferation, which was tested here with an MTS assay, and an
increase o f respiratory burst activity, which was tested with nitroblutetrazolium (NBT).
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Using these methods, a 2.5-fold increase in respiratory burst (Figure 28A) and a 38%
decrease in cellular proliferation (Figure 28B) were observed in cells treated with 8-CPTcAMP for 3 days. A 30% decrease in cell number was observed in treated cells relative
to untreated cells by hemocytometer analysis (data not shown), which is in agreement
with the values obtained from the MTS assay (Figure 28B). There was also no apparent
difference in cellular viability between treated and untreated cells after three days as
determined by trypan blue exclusion under a hemocytometer (20% decrease in viability
in both treated and untreated cells, data not shown). The results from the MTS and NBT
assays demonstrate that a three-day treatment with 50 pM 8-CPT-cAMP is sufficient to
initiate differentiation in U-937 cells and these results are in good agreement with
published work showing U-937 differentiation in the presence o f forskolin and dbcAMP
(176). Kinase Activity in Whole-Cell Extract - While Cy, C a, and CP all bind to the
regulatory subunit and can be specifically differentiated from other kinases by their
cAMP-dependence, a key difference among them is that C a and Cp are inhibited by PKI
(ICgo = 5-12 nM (95)) and Cy is not (IC5Q > 90,000 nM (20)). The conditions set for the
kinase assay make the assay very specific for PKA. These include measurement o f
activity in the presence o f cAMP and the use o f a PKA-selective substrate used at a
selective concentration. The use o f cAMP in this assay alone makes this assay specific
for PKA, for o f the 518 kinases identified in the human kinome, only one has been
described as cAMP-dependent, and that is PKA. The difference in PKI-sensitivity
between the isoforms was exploited here to identify Cy-associated kinase activity in the
cell. Cy-associated kinase activity is defined here as cAMP-dependent, PKI-insensitive
kinase activity measured in the presence o f the PKA selective substrate,
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F ig . 28. 8-CPT-cAMP induces differentiation in U-937 cells. U-937 cells
were treated for three days with 50 pM 8-CPT-cAMP and markers for
differentiation were determined. A, acquisition o f respiratory burst activity was
determined by reduction o f Nitrobluetetrazolium and B, proliferation was
determined using MTS proliferation assays as described in Materials and
Methods. Bars represent the average o f five experiments with (*) indicating
statistical significance relative to control in each experiment. Error bars
represent the standard error for each condition.
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Kemptide. This is in contrast to C a-associated activity, which is defined as cAMPdependent, PKI-sensitive kinase activity measured in the presence o f Kemptide.
Measurement o f kinase activity in cell extract showed total cAMP-dependent activity did
not change

appreciably

in differentiated

cells

(723

pmol/min/mg)

relative to

undifferentiated cells (703 pmol/min/mg) (Figure 29). Flowever, cAMP-dependent, PKIinsensitive activity increased from 186 pmol/min/mg in undifferentiated cells (26% o f
total activity) to 270 pmol/min/mg in differentiated cells (37% o f total activity) (Figure
29). This result suggests an increase in Cy-associated kinase activity during or following
differentiation.
DEAE Chromatography Profiles o f Undifferentiated and Differentiated U-937 Cells - To

determine the effect o f the cAMP-analogue on U-937 cell’s PKA profile, the extracts of
treated and untreated cells were separated by DEAE column chromatography. Kinase
activity profiles were generated using four different conditions (± cAMP, ± PKI) for each
fraction collected from a 50 mL, 0-500 mM NaCl gradient elution. The profile shows
that U-937 cells underwent a shift from 36% type I, 64% type II PKA (Figure 30A) in
undifferentiated cells to 100% type I PKA in differentiated cells (Figure 30B) after three
days o f treatment with 8-CPT-cAMP. The total activity in undifferentiated cells under
peaks I and II was 6111±1267 pmol/min/mg, while in treated cells the activity shifted
completely to type I, 7271±1922 pmol/min/mg (±SE, n=3). The total PKI-insensitive
activity eluted from the DEAE column from undifferentiated cells was 738±146
pmol/min/mg, while from treated cells this activity was 828±405 pmol/min/mg (±SE,
n=3).
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F i g . 29. 8-CPT-cAMP-induced differentiation increases Cy-associated
PKI-insensitivity, cAMP-dependent activity in U-937 ceils. U-937 cells
were differentiated as described in the legend to Figure 1 and Materials and
Methods. Protein kinase activity was determined with Kemptided as
substrate in the presence and absence o f cAMP and PKI (see Materials and
Methods). Each bar is divided into PKI-sensitive (dotted section o f bar) and
PKI-insensitive (stripped section o f bar) activity from total cAMP-dependent
kinase activity. PKI-insensitive activity is also indicated as a percent o f total
activity above each corresponding condition. Each bar represents an average
of five experiments and the error bars represent the standard error for each
condition.
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F ig . 30. 8-CPT-cAMP-induced differentiation of U-937 cells
shifts the PKA profile to the type I isoform. U-937 cells were
differentiated as described in the legend to Figure 28 and in the
Materials and Methods section. Cell extracts were separated by
DEAE-sepharose chromatography , A, before or, B, after treatment
with 8-CPT-cAMP and analyzed for Kemptide kinase activity in
the presence o f cAMP (10 pM) and the presence and absence of
PKI (lpM ). The profiles are representative of three independent
experiments.
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The DEAE profile also shows that in undifferentiated cells approximately 60% of
cAMP-dependent, PKI-insensitive activity is associated with type I PKA and remains
associated with type I PKA in differentiated cells (Figure 30A).
Immunoblot Analysis o f U-937 Cells - A difficulty with selectively identifying Cy
expression in cells and tissues has been the absence o f an antibody that selectively
detected this isoform. Both PKA catalytic subunits C a and Cy share 83% identity, but
only 58% identity at the amino terminus (amino acids 1-40). Santa Cruz Biotechnology
and Abgent developed polyclonal antibodies (pAb) to this region o f Cy. These antibodies
were tested here for selectivity on serially diluted (20-1.25 ng) purified C a and Cy (each
o f 40kDa apparent molecular weight). The antibody from Santa Cruz detected both
purified recombinant isoforms, while the antibody from Abgent only detected
recombinant Cy at all protein levels tested except at 1.25ng (Figure 31 A). The only
discernible difference between C a and Cy with the Santa Cruz antibody is that Cy
provides a better signal (darker band) than C a, which allowed for cell extracts, the
antibody, or both to be titrated to the point where the antibody only detected Cy (data not
shown). However, this approach was not practical since C a is expressed in all tissue
types, and Cy expression in any tissue type has yet to be characterized other than in
human testes (45). The Santa Cruz antibody has recently been used to incorrectly identify
expression of human specific Cy in rat cells (109), indicating the importance of
demonstrating the selectivity and limitations o f these antibodies. Based on our result the
Abgent antibody was used to probe membranes with extract from differentiated and
undifferentiated U-937 cells (Figure 3 IB).
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F ig . 31. Immunoblot analysis demonstrates expression of both C a
and Cy in U-937 cells. A, two commercially available polyclonal
antibodies made against Cy-peptides were tested against purified
recombinant Cy and C a. Lanes were loaded with between 1.25-20 ng of
protein as indicated by the shaded bar over each blot. B, the Abgent antiCy-antibody was tested against blots with differentiated and
undifferentiated U-937 cell extract. The lower pnael in this figure is
presented as an inverted image to aid visualization of the Cy-band.
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The antibody detected a 40kDa band only in extract from differentiated U-937 cells
suggesting Cy expression increases during or following differentiation. An anti-Ca
selective monoclonal antibody (105) was used to determine C a expression levels before
and after U-937 differentiation (Figure 3 IB). This antibody detected similar levels o f C a
expressed before and after differentiation, suggesting C a protein levels do not change
during the period tested.
RT-PCRJRFLP Analysis o f U-937 Cells - Because o f the high homology between C a and
Cy, it has not been possible to design primers that selectively amplify only one mRNA
from the two isozymes, something we have attempted numerous times with no success.
However, the specificity of this RT-PCR allowed for the selective amplification o f only
C a and Cy transcripts in human cells. The primer set used for the PCR step amplifies a
370 base pair region o f both C a (284-654nt) and Cy (256-626nt) transcripts and was
designed to prevent the amplification o f the C(3 isoform.

No bands other than the

expected 370 bp amplicons were observed.
To differentiate the amplicons, an adaptation o f the restriction fragment length
polymorphism (RFLP) protocol was developed (Figure 32A).

The C a amplicon

sequence does not contain a PstI digestion sequence, but PstI cleaves the Cy amplicon
into fragments o f 254, 86 and 31 base pairs. The restriction enzyme Xhol does not cut the
Cy amplicon but cleaves the C a amplicon into fragments of 255 and 116 base pairs. In
addition, the restriction enzyme Rsal cleaves both amplicons, yielding different
fragments o f 207 and 164 base pairs for C a, with 149, 106, and 101 base pairs for Cy.
The Rsal reaction would also serve to identify any potential amplification o f the C(3
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isoforms, since expected patterns for this fragment are bands o f 165 and 106 base pairs.
These contaminating bands were not observed.
Both C a and Cy RT-PCR/RFLP fragments were detected in control U-937 cells.
Ca-specific fragments were seen as Rsal digests o f 206 and 165bp (data not shown),
Xhol digests o f 255 and 116bp, and the band not cut by PstI (Figure 32B). The Cyspecific fragments were seen as Rsal digests o f 148, 106, and lO lbp (data not shown),
PstI digests of 254, 86bp and 31bp, and the band not cut by Xhol (Figure 32C). The RTPCR/RFLP analysis o f undifferentiated and differentiated U-937 cells demonstrated that
both C a and Cy RT-PCR fragments are seen on days zero through day two in untreated
and treated U-937 cells (Figure 32B). However, by day three, Cy RT-PCR/RFLP
fragments were still visible while no apparent C a transcripts were detected in treated U937 cells (Figure 32C).
DISCUSSION
Until now Cy was believed to be a testes-specific PKA isoform, identified only
through the cloning o f its mRNA. Here for the first time we demonstrate the expression
o f active endogenous Cy protein from an in-cell system. The hypothesis put forth in this
paper was that Cy expression occurs in cells undergoing differentiation, regardless o f the
cell’s tissue source. Here we present, for the first time, evidence that Cy is expressed in
cells from tissues other than the testes. Furthermore, because Cy mRNA is present before
differentiation,

and protein

expression

and kinase

activity

increases

following

differentiation, it is possible that Cy has a function in cellular differentiation. U-937 cells
are a human histiocytic lymphoma cell line (189),
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F ig . 32. Differential expression of C a and Cy mRNA in U937 cells during
8-CPT-cAMP induced differentiation. Control and 50 pM 8-CPT-cAMPtreated U-937 cells were isolated on days 0, 1, 2, and 3 and total RNA was
isolated as described in Materials and Methods. A, scheme o f expected
fragments from restriction enzyme digest o f RNA for each isoform as indicated
to the right of the figure. Restriction enzyme digests of RT-PCR products was
done using, B, Xho I or, C, Pst I for analysis o f C a and Cy expression,
respectively. Each gel is representative o f three independent experiments.
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a transformed

pre-monocytic

cell

line

that has

retained

some pre-monocyte

characteristics but capable o f fully differentiating. About 20-30%
o f the cells in culture exhibit differentiation markers at any given time, such as
phagocytic activity and the expression o f Fc receptors (189).However this cell line is
considered by many to be a useful model for cellular differentiation because o f its
increased response to pro-differentiation agents such as TPA, IFNy and cAMP, while not
becoming terminally differentiated. We utilized the cAMP-PKA pathway to induce U937 cell differentiation and investigate Cy expression during cellular differentiation.
Cellular differentiation was determined through two well-characterized differentiation
markers that include highly specialized functions exhibited by differentiated cells. These
included cell growth arrest and increased respiratory burst activity. U-937 cells exhibit
differentiation markers when treated with cAMP-signaling pathway agonist such as
forskolin and dbcAMP (176,185,190), but there are inherent problems with each o f these
reagents, such as metabolic byproducts and degradation o f endogenous cAMP by PDE.
Therefore, we opted to use 8-CPT-cAMP, another membrane permeable, cAMPanalogue, which was less susceptible to degradation by cAMP PDE (10). Three days of
treatment with 8-CPT-cAMP induced reduced cell growth rate without decreasing
cellular viability, while increasing the cell’s respiratory-burst activity. Both markers are
used to

identify pre-monocytic

cellular differentiation

to

macrophages.

While

differentiation o f U-937 cells with a cAMP analogue has been described before, this is
the first time it has been demonstrated with 8-CPT-cAMP and the first time that Cy
expression at the mRNA and protein level have been detected in any cell.
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An increase in cAMP-dependent, PKI-insensitive kinase activity was measured in
U-937 cells treated three days with 8-CPT-cAMP, suggesting an increase in Cy protein
expression following differentiation. While the apparent increase in Cy activity may
appear modest, changes in cAMP-dependent functions do not require large changes in
cAMP or PKA enzyme activity. Furthermore, total cAMP-dependent kinase activity did
not increase. Since the maximal velocity o f Cy is significantly lower than that o f C a (20),
the real change in Cy activity may be underestimated based on a comparison with C a. In
addition, Cy does not bind PKI and therefore will not be exported from the nucleus by the
same mechanism for C a. Thus the real impact o f Cy expression on transcription is
uncertain. While transcriptional regulation by the two isozymes is different, the real role
for Cy-regulated transcription remains to be determined, but difference may be related to
cell events such as cellular differentiation. While it has been demonstrated that Cy
appears to be more PKG-like, preferring substrates with differences on the carboxyltermini o f the phosphorylation site (20), the physiological meaning for differences in
substrate specificity between the isozymes in vivo remains to be determined. What
remains perplexing is a potential role for Cy that is specific to primates.
A more readily recognized change following U-937 cell differentiation was the
PKA profile, which shifted from a type I: type II ratio o f 0.64 in undifferentiated cells to
100% type I in differentiated cells, with Cy activity prevalently associated to type I PKA.
A similar trend has been observed in Chinese hamster ovary (CHO) cells treated with
dbcAMP (7), although the loss o f type II PKA following treatment with dbcAMP was not
as dramatic in CHO cells. This is mostly likely due to differences in cell types. CHO is a
hamster epithelial cell line and U-937 is a human hematopoietic cell line. Increases in
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Riot in response to treatment with cAMP analogues have also been observed in cultured
fibroblast and Rat-1 cells (7). This implies that an increase in intracellular cAMP serves
as a positive feedback signal for R Ia expression, and that R Ia is part o f the cell’s
differentiation mechanism. However, PKA function in cellular differentiation is still not
clear.
The stable level o f total kinase activity present in the cell before and after
differentiation suggests that a basal pool o f potential PKA activity is maintained in the
cell irrespective o f the cell’s differentiation status. Maintenance o f total PKA activity
levels in the cell may be achieved through compensation by differential expression o f the
catalytic subunit isoforms. An example o f this is seen in C(31 knockout mice, where total
kinase activity does not decrease in the absence o f Cpi (58), suggesting that Ca
compensates for the loss of C(31. Thus, an increase in Cy expression in U-937 cells during
differentiation may be offset by a decrease in C a expression to maintain a constant
kinase activity level in the cell. This is supported by the result showing C a, but not Cy,
mRNA decreased following three days o f treatment with 8-CPT-cAMP, while C a protein
levels did not decrease based on immunoreactivity with the putative C a antibody. The
possible presence o f C a protein in the absence o f its RNA may be due to the stability of
the PKA catalytic subunit, which has a 9.2 hour half-life when bound to the regulatory
subunit (79). Alternatively, it is possible that the cAMP-dependent, PKI-sensitive activity
observed post-differentiation is due to Cp, since immunoreactivity between C a and CP
with these antibodies has not been verified. While there is no precedent for CP
compensation for a loss in C a, C-subunit isozyme shifts have not been closely analyzed
in a differentiation paradigm. However, a compensation o f Cy for C a activity would
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require a considerable increase in Cy catalytic activity since the V
lower than the C a

m ax

is at least 10 times

(20). Nevertheless, about 90% o f PKI-sensitive activity in U-937

cells was present in the holoenzyme form (activity ratios were 0.04 in untreated cells and
0.13 in treated cells, data not shown). Based on these results, further analysis o f Csubunit isozymes during U-937 cell differentiation is warranted. It is especially
noteworthy that Cy catalytic activity and immunoreactivity increases after 8-CPT-cAMP mediated differentiation in U-937.
One major advance and important development demonstrated here is the
identification o f an antibody that is relatively specific for Cy that has allowed the
unequivocal differentiation o f the Cy- and Ca-subunit isoforms. Antibodies to
specifically identify Cp remain unavailable. The Cy antibody detected a 39-40 kDa band
that appeared following, but not prior to, differentiation and was concurrent with the
increase in Cy-associated kinase catalytic activity. The antibody did not detect this band
prior to differentiation, possibly because Cy expression levels were below the detection
limit o f the antibody. The kinase assay used is very sensitive (10) and thus, likely to
detect Cy-catalytic activity before an antibody detects the protein. While immunoblot
analysis with different antibodies does not allow quantification o f C-subunits, the
increase in cAMP-dependent, PKI-insensitive kemptide kinase activity following
differentiation provides a valuable tool to differentiate and quantify changes in Cy
activity. The low PKI-insensitive specific activity relative to PKI-sensitive, cAMPdependent activity may be due to low Cy expression levels and/or lower Cy

relative

to C a (20). Thus, while it is clear that Cy expression increases following differentiation,
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because the two isozymes are so different kinetically, it is problematic to compare them
on an activity basis. It is intriguing that the homology o f the two isozymes is so high, yet
specific identification of their respective mRNAs is problematic. Thus, it has not been
possible readily to differentiate and quantify the mRNA levels o f Cy and C a. While C a
and Cp have higher homology than Cy and C a, there are differences that complicate
specific Cy identification. First, differences between Cy and C a do no occur in clusters,
but are spread out through the sequence, making it difficult to find specific primers. In
addition, C a and Cp can be easily differentiated in their 3 ’ un-translated sequences,
which are highly homologous in Cy and C a. Clues to differences in transcription targets,
which are likely to reveal potential roles for Cy in differentiation, have also been difficult.
However, potential differences in compartmentalization provide further avenues for
investigation. Because Cy appears preferentially to associate with the RI subunit, the type
I PKA is often predominant in differentiated tissues, and the different localization o f type
I and type II (191), suggest that compartmentalization o f type I-Cy is likely to play a
functional role that remains to be determined. It is interesting in this regard that activation
o f type I PKA is sufficient to inhibit T lymphocyte proliferation (192).
The presence o f Cy in the primate genome for 40 million-years suggests a
potential role for this cAMP-dependent, PKI-insensitive kinase in human function and the
result here suggest a role in differentiation. However, it cannot be ruled out that it is a
human genome remnant that has not experienced evolutionary selective pressure. The
function o f Cy in the cell remains to be unequivocally elucidated but the results presented
here and elsewhere (13,20,105) suggest that differences observed between Cy and C a in
stable transfections (5) and in vitro biochemical experiments (20) may manifest
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themselves during cellular processes such as cellular differentiation. Cy-association with
type I PKA, the only isoform present following differentiation, the increase in Cyassociated activity following differentiation, and the presence o f Cy mRNA before and
after differentiation all support the idea that Cy may have a function in cellular
differentiation that is distinct from the other isoforms.
Identification of functional Cy protein expressed in the cell completes the Cy
central dogma (i.e. gene expresses the messenger RNA, which in turn expresses the
functional protein) where the gene (106) and mRNA (45) had previously been identified
in the cell. Presented here are the concurrent identification o f both the mRNA and the
protein in the U-937 cell line. The presence o f Cy mRNA before and after differentiation
hints at the possibility for Cy post-transcriptional regulation, something suggested for
R Ia (reviewed in (193)). This would add another regulatory step for this isoform; other
steps include transcriptional (through a CG-rich promoter) and post-translational (via
phosphorylation) regulation. Now that an antibody selective for Cy is available, it may be
possible to study the dynamics o f Cy expression and localization in the cell in order to
understand regulation of this isoform. While this work raises many questions about Cy it
clearly demonstrates for the first time that functional Cy is expressed in human cells
during a very specific cellular process.
The results indicated here suggest that there is a switch in both R and C-subunit
isoforms during the cAMP differentiation program in U-937 cells. However, the
regulation of R- and C-subunit levels is obscure. The C-subunits are downstream o f
TATA-less promoters, which are often regulated as housekeeping genes and associated
with constitutive expression. Thus, the levels o f the subunits themselves may be regulated
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at the level o f mRNA and/or protein. C a protein has a half-life o f less than 10 hours,
suggesting that the protein is turned over rapidly, but turnover before and after
differentiation in U-937 cells has not been analyzed. It is interesting that three days after
initiation o f differentiation by 8-CPT-cAMP, the C a mRNA is not observed while the
presence o f cAMP-dependent, PKI-sensitive activity is present. It is not clear at this time
if this is due to C a and/or Cp activity, but it is possible that the C a mRNA is turned over
rapidly as it is in S49 cells (79, 80), while Cy continues to be expressed.
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CHAPTER VI

SUMMARY AND CONCLUSIONS

SUMMARY
The ideas for the work addressed in this dissertation came from two sources. The
first one was from a National Institute o f Health Grant (GM44777) awarded to Dr.
Stephen J. Beebe designed to study C a and Cy in order to understand protein kinases
structure-function relationships in this protein family, which is one o f the largest groups
o f evolutionarily conserved protein families in the human genome. The second source
was an American Physiological Society Pre-Doctoral Porter Fellowship for Minorities
awarded to this Ph.D. candidate. Within this fellowship three specific aims were outlined
to address this dissertation, which came out this Ph.D. candidate understanding the theory
and specific aims described and outlined in Dr. Beebe’s NIH Grant. The three specific
aims addressed in this dissertation were: 1) to identify differences in primary structure
between PKA-Cy and PK A -Ca that defines their physiological function in intact cells
(Chapter II); 2) to characterize post-translational differences between purified PKA-Cy
and PK A -C a that defines their physiological function (Chapter III); and 3) to characterize
the kinetic mechanism for PKA-Cy through determination o f the rate constants for each
catalytic step o f the phospho-transferase reaction (Chapter IV). The results from a fourth
objective were presented here, which was to address the question, is Cy expressed in
differentiating cells? (Chapter V). The work presented in chapters III and V is currently
being submitted for publication, thus each chapter was presented in this dissertation in the
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format o f an independent manuscript to facilitate extracting each chapter for publication
purposes. This work also follows up on research initiated by Dr. Wei Qing Zhang done
for his dissertation under the guidance Dr. Stephen J. Beebe. To the best o f my
knowledge there is currently nobody else doing research that focuses on characterizing
the PKA-Cy catalytic subunit. Following are summaries of the findings presented in this
dissertation (Chapters II-V). The summaries are derived from the abstracts presented at
the beginning o f each chapter.
Specific Aim 1: To identify differences in prim ary structure between PKA-Cy and PKAC a that defines their physiological function in intact cells (Chapter II )- This hypothesis
was tested here with chimera constructs wherein the first 50 and terminal 70 amino acids
were swapped between C a and Cy and tested through transient transfections with CREBmediated reporter assays. While both isoforms induced transcriptional activation, the
chimera transfections failed to exhibit any activity in COS7 cells, but exhibited some
activity in Kin8 cells. This difference in cell type dependent activity may suggest that
there are cell type specific factors that are required for the proper expression o f the
chimeras. Immunoblot analysis demonstrated that each o f the chimeras was expressed in
COS7 cells and sequence analysis o f the constructs suggests that the expressed chimeras
should have the expected primary sequence. While it is difficult to interpret the results
obtained from the chimera studies the amino and carboxyl terminals remain important
regions o f divergence between C a and Cy that warrant further studies.
Specific Aim 2: To characterize post-translational differences between purified PKA-Cy
and PK A-C a that defines their physiological function (Chapter III)- Differences in
phosphorylation between C a and Cy were studied here through reporter assays using Cy
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and C a T197 point mutants, immunoblot analysis using an anti-phospho T197 selective
antibody and LC-MS/MS phosphomapping o f purified recombinant proteins. Two novel
phosphorylation sites were identified on both isoforms by LC-MS/MS analysis (Cy pS14
and C a and Cy pS259). It was also determined that Cy is phosphorylated homologously
to mammalian expressed C a (pT197 and pS338) and the modification at T197 is
important to the function of both isoforms suggesting that differences in posttranslational modification are not the reason for kinetics differences observed between
these two isoforms.
Specific Aim 3: To characterize the kinetic mechanism fo r PKA-Cy through determination
o f the rate constants fo r each catalytic step o f the phosphotransferase reaction (Chapter
IV )- Here recombinant C a and Cy binding rates for ATP and ADP were compared
through

stopped-flow

analysis,

using

ATP

and

ADP

conjugated

to

a

N-

methylanthraniloyl (mant) fluorophore. Using this approach the Ca-A TP on and off rates
were determined and found to be in good agreement with the literature. The C a release of
ADP was slower than the release o f ATP, which is in agreement with ADP release being
the rate-limiting step. However, several other slow rates were measured for both the
mant-ATP on and off rates, which may suggest that mant-ATP is not the rate-limiting
step. But the work presented here was unable to clarify this question. The homogenous
purification o f recombinant hisg-Cy proved to be difficult but enough was attained to
measure the Cy ADP-off rate, a step where divergence in the catalytic mechanism of
these two isoforms could explain differences in biochemical function. The signal
measured for the Cy ADP off-rate was reproducible but very low and needs to be
repeated in another independent experiment. However, the measured ADP-off rate for C a
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is about 9-times faster than that o f Cy, a result that is in agreement with differences in
their steady-state kinetics. While it is still not clear what structural differences between
C a and Cy lead to functional differences it is encouraging to identify a difference in their
catalytic rate. The physiological ramifications o f the biochemical difference between C a
and Cy still needs to be determined through studies o f the isoforms in vivo and in the
intact cell.
Is Cy expressed in differentiating cells? (Chapter V)- For the first time we present the
selective identification o f endogenous Cy protein and mRNA expressed in human U-937
cells. Increases in protein kinase inhibitor (PKI)-insensitive, cAMP-dependent kinase
activity following 8-CPT-cAMP-induced differentiation o f U-937 cells suggested an
increase in Cy expression during differentiation, while total PKA catalytic activity did not
change. A new Cy-specific antibody identified a 40-kDa band following differentiation o f
U-937 cells and RT-PCR/RFLP analysis demonstrated that Cy mRNA was present before
and after differentiation. DEAE chromatographic analysis of U-937 cells showed that the
PICA profile changed from similar levels o f type I and type II PKA in undifferentiated
cells to 100% type I in differentiated U-937 cells. Furthermore, 60% o f PKI-insensitive,
cAMP-dependent activity in U-937 cells was associated with type I PKA suggesting Cy
favors association with type I PKA in this cell line. These results expand our
understanding o f structure-function roles for PKA isoforms in cell differentiation and
function. Furthermore the increase in Cy expression during U-937 differentiation suggests
a novel function for Cy in the cell.
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CONCLUSIONS
In order to identify causes for biochemical differences between C a and Cy both
the primary structure and modified structure o f C a and Cy were compared and
characterized. The two isoforms were also characterized for differences in their catalytic
mechanism and analyzed for expression patterns in the cell. The results from the chimera
studies, where portions o f the amino or carboxyl terminals were swapped between C a
and Cy, remain inconclusive. This makes it hard to interpret the significance o f the amino
and carboxyl terminal regions to the function o f the catalytic subunits. Studies o f these
regions have been done successfully with C a through the characterization o f point
mutants and have demonstrated that these regions are important to the enzymes stability
and substrate recognition. As Cy seems to be more labile than C a but still functional, it
seems likely that differences in these regions will eventually help address physical
differences between C a and Cy that contribute to their functional differences. The amino
terminus is o f particular interest because this region is where there is the greatest
divergence from homology between C a and Cy and among C-subunit isoforms among
species. Furthermore the amino terminus contributes to overall structural stability o f Ca.
Because the C a amino and carboxyl domains fall outside o f the conserved kinase
catalytic core it is difficult to draw from studies on these regions in other kinases. In most
kinases these regions are a lot more extensive than in C a and Cy and the functions for
these domains are very diverse, ranging from protein-protein interactions, localization
signals, and regulatory functions, depending on the kinase.
A feature conserved amongst most kinases is the phosphorylation o f the catalytic
loop. Most, if not all, kinases need to be phosphorylated in this region to be active. And
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many o f them need to be phosphorylated on the catalytic loop to be fully functional.
Studying the phosphorylation state o f C a and Cy addresses an important question: can a
kinase be active in the absence o f phosphorylaion on its catalytic loop? Because
phosphorylation differences on the catalytic loop were not found between C a and Cy,
which is the only modification shown to date to be o f significance to the function both
isoforms, functional differences between C a and Cy do not seem to be due to
phosphorylation differences. Two novel phosphorylation modifications were identified
on Cy and C a and it will be o f interest in future studies to determine if these
modifications are important to the function o f either catalytic subunit. It will also be of
interest to compare these modifications with other kinases to determine if these are
conserved among other kinases. Thus, the studies presented in the Chapters II and III
have not demonstrated physical differences between the catalytic subunits to which
functional differences can be attributed.
A likely explanation for functional differences was observed upon studying the
catalytic mechanisms o f each C-subunit. The catalytic mechanism for C a has been
studied in great detail, and while the literature clearly favors an ordered Bi Bi mechanism
with the release o f ADP as the rate-limiting step, it is also clear from the same literature
that many questions remain about this mechanism. Here it was found that the “ratelimiting” step is much slower for Cy than for C a. Thus, it is very possible that functional
differences are due to differences in their ADP off-rates. The simple explanation for this
observation is that C a and Cy exhibit differences in their overall tertiary-structure, which
may affect the conformation o f the isoforms and binding o f the substrates. This
measurement may explain why Cy exhibits slower kinetic and reporter activities as these
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mechanisms depend on phosphorylation by the C-subunits. Thus Cy would phosphorylate
0.1 of the substrate molecules that C a would, causing a ten-fold difference in kinetic or
reporter-activity measured, which is what is observed in most instances.
The most elusive fact about Cy has been the absence o f its expression identified in
the cell. Here for the first time Cy expression has been identified in differentiating cells.
The appearance of Cy in differentiated U-937 cells suggests a novel role for PKA in this
cellular process.
While the results presented here fail to identify specific physical differences that
could define functional differences between C a and Cy, the same results have helped us
understand the significance o f phosphorylation to the catalytic loop o f the enzyme, for
without this modification both kinases lost all o f their function. Furthermore, Cy is a
functional kinase that is expressed in the cell during specific cellular events such as
differentiation, and has survived 40 million years in the human genome. So while the
nature o f Cy function in the cell remains elusive, it is likely that the manifestation o f the
functional differences between C a and Cy will eventually be observed when the tools to
knock out Cy or C a without disrupting the other isoform are developed. But the present
results suggest that during some cellular events, such as differentiation, it seems
important that a cAMP-dependent kinase with slower kinetics and reporter activity than
C a be expressed, while C a expression be suppressed.
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APPENDIX A

PERSONAL COMMUNICATION FROM TONY HUNTER ON THE ORIGIN OF
THE TERM KINASE

Dear Dr. Hunter,
I am a graduate student in Dr. Stephen Beebe's laboratory characterizing PKA-Cgamma.
You may not recall but we met very briefly at a second messenger Gordon Research
Conference in 2001. I have enjoyed reading many o f your reviews and learned a great
deal through these. Recently I have been curios about the history o f kinases, when they
were first discovered and where the name "kinase" came from as this is not a proper
name for an enzyme, according to IUBMB, as kinases are phospho-transferases. Could
you recommend a good source or reference from which to obtain this type o f information
on kinases. The earliest publication I could find in PubMed with kinase in it was 1963,
and this was a German paper, I do not recall the authors. I would appreciate any
information you could share with me on this matter.
Sincerely, Gary
From: Tony Hunter [mailto:hunter@salk.edu]
Sent: Thursday, January 30, 2003 9:20 PM
To: Morris, Gary Z.
Subject: Re: Question about the origin o f the name "kinase"(?)

Gary - You really need to address this question to one o f the old timers in the field like
Ed Krebs, but I'll give it a shot. Although
phosphoproteins had been known since the 1930's, the first protein kinase activity to be
detected was casein kinase (actually we now know this was CK2) by Kennedy in 1954
(JBC 207:153; JBC 211:969; see Annu. Rev. Biochem. 61:1). For a history o f protein
phosphorylation, you might look at Cohen (Nature Cell Biol. 4:E127). The word kinase
derives from the Greek kinein, which means to move towards, and in this context it is
moving the phosphate from ATP onto an acceptor (e.g. hexose or protein). I hope that
this is helpful. Tony
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APPENDIX B

CONSTRUCTION OF CHIMERAS

O r i g in a l M e s s a g e -------

From: zhang98 [mailto:zhang98@uic.edu]
Sent: Monday, November 11, 2002 12:31 PM
To: Beebe, Stephen
Subject: construction o f C-subunit chimera
Hi Dr. Beebe:
I am sending you the procedure how to make those chimera as
attached file and the following. Any question, please call me. thans.
John
Construction o f Ca Chimera containing cDNA encoding aal to aa 50 of
Cg sequence and Cg Chimera containing cDNA encording aal to aa 50
o f Ca sequence:
Human Ca an d Cg chimera cDNA were subcloned via the H indlll and EcoRI sites into
the pCMV5 (Invitrogen). The splicing sites o f the chimeras mapped to highly
differeciated regions o f PKA catalytic subunits (the first 50 amino acids sequence). The
chimeric constructs were then generated by repeated cycles o f two-step polymerase chain
reaction overlap extension (Horton et al 1989) with the Ca and Cg cDNA containing
plasmids as templates, espectively. The cDNAs were fused sequentially at homology
regions o f splicing site RS with the primers listed in Table I. Primers Ca-A/Cg-A and
Ca-D Cg-D provided Hind III and EcoRI linkers, respectively, for subcloning into
pCMV5. The correct sequence o f the final products was confirmed by automated
sequencing.
Table
Oligonucleotide primers for splicing by overlap extension polymerase chain reaction. For
the internal primers, the bold primer sequence letter denote the locations o f the
corresponding splicing sites coding sequences or their reverse complements, respectively.
Name Sequence
Sense/antisense
Internal primers
Ca-B 5' CTGGTGCCTCACCAGCATCACTCGCCCAAAGGAGCCGGT (s)
Cg sequence for overlapping
Ca-C 5'ATGCTGGTGAAGCACAAGGAG (AS)
Cg-B 5' CTTGTGCTTCACCAGCATCACCCGCCCGAAGGAGCCCAT (S)
Ca sequence for overlapping
Cg-C 5'ATGCTGGTGAGGCACCAGGAG (AS)
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External primers
Ca-A 5'-ATATAAGCTTATGGGCAACGCCGCCGCCGCC (S)
Ca-D 5'-ATATGGATCC CTAAAACTCAGTAAACTCCTT (AS)
Cg-A 5'-ATATAAGCTTATGGGCAACGCCCCCGCCAAG (S)
Cg-D 5 '-AT AT GG ATCCCT A A A ACT C AG A A A ACT CCTT (AS)

Original Message----From: zhang98 [mailto:zhang98@uic.edu]
Sent: Wednesday, September 22, 2004 11:17 AM
To: Morris, Gary Z.
Subject: RE: Hey John

Hey Gary:
Sorry for the delay because thing up here become pretty taugh. Now I
am sending you the sequence I designed for Chimera at 280 aa after.
1) Cg-a-5' (1 )CAAGAACTCCAAGGGTTTGCGCTTGGTGAGGTCCAC
2)Cg-a- 5'(2) A A ACCCTT GG AGTTCTT GGGGGT C A AT G AC AT CA AG
3)Ca-g-5'(l)CAAGGACTCCAAAGGCTTGGCGCTTGGTGAGATCCAC
4)Ca-g-5;(2)AAGCCTTTGGAGTCCTTGGGGGTTGGCGACATCAAG
Please take a look and synthesize them in HPLC scale. Send them to
me while you have them. I will let people done as soon as possible.
Thanks.
Regards
John

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

156

APPENDIX C

ELSEVIER COPYRIGHT PERMISSION

w

Nfri; ivmnicinnrate the founding
u f ik e 1 lo o s e n f KUcvii
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a n c c e i e h u ic ih e c s u h u ..n m
OS I . t l £ I ’i i C v i C t C O L H jJU J .

16 June 2005

1
)

.‘‘ S i t .

Our ref: HG/mm/jun 05.J063

M r Neil Reece
ReeceNM@CHKD.COM
For: Gary Morris
Dear Mr Morris
ARCHIVES OF BIOCHEMISTRY & BIOPHYSICS, Vol 403, pp 219-228, Morris et
al, "Differential..." 1 Figure only
As per your letter dated 6 June 2005, we hereby grant you permission to reprint the
aforementioned material at no charge in your thesis subject to the following conditions:
1.

If any part o f the material to be used (for example, figures) has appeared in our
publication with credit or acknowledgement to another source, permission must
also be sought from that source. If such permission is not obtained then that
material may not be included in your publication/copies.

2.

Suitable acknowledgment to the source must be made, either as a footnote or in a
reference list at the end o f your publication, as follows:
"Reprinted from Publication title, Vol number, Author(s), Title o f article, Pages
No., Copyright (Year), with permission from Elsevier".

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

157

3.

Reproduction o f this material is confined to the purpose for which permission is
hereby given.

4.

This permission is granted for non-exclusive world English rights only. For other
languages please reapply separately for each one required. Permission excludes
use in an electronic form. Should you have a specific electronic project in mind
please reapply for permission.

5.

This includes permission for UMI to supply single copies, on demand, o f the
complete thesis. Should your thesis be published commercially, please reapply
for permission.

Yours sincerely

Helen Gainford
Rights Manager

Your future requests will be handled more quickly if you complete the
online form at w w w .elsevier.com /locate/perm issions
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APPENDIX D

DETERMINATION OF TRANSFECTION EFFICIENCY

Fluorescent image o f COS7 cells transfected with a pCM V5 RI-GFP
expression vector to determine transfection efficiency using Fugene 6.
Transfection efficiency was determined as a percent by the ratio of
fluorescent cells counted under fluorescent light over total cells counted
under white light in the same field (xlOOO magnification, under oil
emersion, on a Ziess Axioscope fluorescent microscope). A minimum of
200 cells/transfection experiment were counted.

The transfection

efficiency was determined to be 22 ± 5 % (average ± standard deviation).
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APPENDIX E

EQUATION TO DEFINE RATE-LIMITING STEP DIFFERENCE BETWEEN C a
AND Cy

Original Message----From: Howard White [mailto:howard_white@hotmail.com]
Sent: Tuesday, June 14, 2005 3:54 AM
To: MorrisGZ@CHKD.COM
Subject: RE: rate limiting step for PKA
I must say that I didn't recall that we obtained a reasonably ok result with gamma.
Assuming that was the case there could be a relationship between the ADP
dissociation and steady state rates - but I need to reread the papers. Could you
either send me a pdf or the reference to the work from the San Diego lab on mant
kinetics? In general the following sort o f mechanism would produce parallel
dependances o f ADP dissociation and steady state rates.
K

k-ADP

M*-ADP <==> M-ADP —> M + ADP
ksteadstate = K x k-ADP

where K = 0.1 o f some steps prior to ADP dissociation is unchanged and k-ADP
is the measured rate o f ADP dissociation. There are other possibilities.

I hope this is o f some help.
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APPENDIX F

MEASURING STOKES RADII OF PURIFIED RECOMBINANT CATALYTIC
SUBUNITS

W. Zhang, G. Z. Morris, S. J. Beebe (2004) Protein Expression and Purification (35)
pp. 156-169.

The Stokes radii (Rs) and molecular weight (MW) for each purified recombinant
catalytic subunit were measured using their elution constant (Kavg). The Kavg for each
subunit was determined as follows: Kavg = (Ve-V0)/(Vr V0) where Ve is the elution volume
of the protein, Vt is the total volume o f the column, and V„ is the column void volume
determined by the elution volume o f blue dextran. A standard curve o f V(-log Kavg) vs.
Stokes radii o f the standard was used to calculate the Stokes radii o f each catalytic
subunit. The standards used to generate each curve were ferritin (440 kD, 61
(158 kD 48.1

A),

albumin (67 kD, 35.5

chymotrypsinogen (25 kD, 20.9

A),

A),

A), aldolase

ovalbumin (43 kD, 30.5

myoglobin (20.2 kD, 20.2

A),

A),

and cytochrome C

(11.7 kD, 17 A).
The correlation coefficient for the Stokes radii was 0.93. These parameters were
determined from a Sephacryl S-300 (320 mL) gel filtration column (Amersham
Bioscience). Four mL fractions were collected and analyzed by measuring OD@280 nm
(Perkin Elmer Lambda 40 uv/vis spectrophotometer). Results were plotted as elution
volume vs OD, and the peak elution for each standard was used as its Ve. Analysis o f C a
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and Cy was carried out during purification following the CM-Sepharose chromatography
and from crude extract with no difference observed on the measured Kavg between the
two sample forms. C a and Cy fractions were tested for catalytic activity using a standard
kinase assay. Total volume loaded onto column for each run was lm L (~ 0.3% o f total
column volume).

The Stoke’s radii for C a was measured at 27.5 ± 0.4
± 0.8

A and for Cy at 24.2

A (the p-value = 0.02).
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APPENDIX G
THROMBIN DIGEST CHARACTERIZATION OF C a AND Cy

A t h r o m b in d i g e s t o f p u r i f i e d r e c o m b i n a n t C a a n d C y w a s d o n e w i t h I n g / p L C - s u b u n it

and 1U o f thrombin (Sigma) in a final volume o f 50 pL o f KP10EDTA1 [6.9] and
incubated at 37°C for one hour. The reaction was stopped by adding 50 pL sample buffer
and incubating at >90°C for 10 minutes. The samples were analyzed by running 5 ng of
C-subunit from each reaction on a 9% acrylamide gel with 4% stacker, transferring to a
PVDF membrane, and treating with a rabbit polyclonal antibody against the carboxyl
terminal o f C a (Santa Cruz Biotechnology) that cross-reacts with both isoforms. The
membrane was incubated with ECL reagent (Amersham Biosciences), imaged by
exposing film to the ECL treated membrane.

Cy

—

>

Ca

Ca
Cy

Cy

Ca
Ca
Throm bin T x q ,

The figure shows that thrombin cleaves the hisio-tag off o f C a, which contains an
RGD thrombin cleavage sequence. But Cy disappears all together with thrombin
treatment and it is not clear why, as the antibody recognizes the C-subunit carboxyl
terminal and the Cy-thrombin cleavage site is on the amino terminus.
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APPENDIX H

DETERMINING C a KMFOR ATP USING PROMEGA’S NON-RADIOACTIVE
KINASE ASSAY

The non-radioactive kinase assay was done according to manufacture’s protocol
(PepTag® Assay for Non-Radioactive Detection o f Protein Kinase C or cAMP Dependent
Protein Kinase catalogue # 5340). Briefly, lp L o f pure recombinant C a (2pg/ml) in PKA
dilution buffer (350mM K 3P04 (pH 7.5) O.lmM DTT) was mixed with 5pi PepTag®
PKA 5X reaction buffer (lOOmM Tris-HCl (pH 7.4) 50mM MgCl2 ), 5pl PepTag®
A lPeptide, and 9pL water in a 0.5ml microcentrifuge tube and kept on ice until 5pl of
the corresponding ATP concentration was added (0-100 pM, final concentrations). The
reaction was initiated by the addition o f ATP and incubating at 30°C for 30 minutes.
Incubating in a heating block at

2 ng cPK Aa with varying
concentrations of ATP

95°C for 10 minutes terminated the

ooo

reaction. Glycerol (lp l o f 80%) was
phosphorylated

added to each sample following
incubation.

Samples

were

then

un-phosphorylated

loaded into a 1% agarose gel and
run at 25V until phosphorylated and non-phosphorylated PepTags were resolved in gel.
The gel was imaged on a VersaDoc (BioRad) and the band intensity was determined
using Quantity One software (BioRad). An Eadie-Hofstee plot was generated from this
data using Band intensity (y-axis) vs. [ATP]/band. The slope o f this curve represents the
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measured C a Km for ATP, which was determined here at 14 pM. This measure is in good
agreement with the published value (25 pM, Zhang et al Protein Expression and
Purification (2004) 35, 156-169).

E a d ie-H o fstee P lot for cP K A a w ith A T P , B a sed on R esu lts from N o n -rad ioactive
K in ase A ssa y
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APPENDIX I

cAMP, KING OF SECOND MESSANGERS

onw o r l wlfli calcium? TaRfc a howand felss If!

Y
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APPENDIX J

STOPPED-FLOW MEASURE OF Ca-MANT-ATP ASSOCIATION RATE IN THE
PRESENCE OF THE PHOSPHO-ACCEPTOR SUBSTRATE, KEMPTIDE

400
350
y = -0.1961x + 296.43
- 300
©
«V5 250

R2 = 0.3865

2 200
0^
I 150
es
a>
g
100
y = -0.0063x + 11.038
R2 = 0.0278

0

100

200

300

400

(micromolar Kemptide)
The mant-ATP on rate

for C a

was measured

here

at 25°C in the presence o f Kemptide to

determine whether the presence o f the second substrate affected the observed binding rate
of the first substrate. This was done by mixing 13 pM C a from one syringe with 100 pM
mant-ATP mixed with varying concentrations o f Kemptide (25-400 pM) in the other
syringe. The slopes for the two rates measured at 25°C, k l (open circles) and k2, (closed
circles) decreased very slightly with increasing amounts o f Kemptide (klKemptide: y = -
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0.1961x + 296.43, R2 = 0.3865; k2 Kemptide: y = -0.0063x + 11.038, R2 = 0.0278), but it is
not clear if these slopes fall within the error measured for each rate. A similar trend is
observed in the amplitudes for each rate (amplitude 1Kemptide: y = -O.OOOlx - 0.1012, R =
0.5346; amplitude2KemPtide: y = -7 x 10'6x + 0.0123, R2 = 0.085). The correlation values
for these curve fits are not very good, suggesting that there is little difference between the
measured rates or amplitudes at each Kemptide concentration.
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APPENDIX K

CALCIUM , K IN G O F SECOND M ESSENGERS
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